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INTRODUCTION 
 
The Philadelphia chromosome: the molecular signature of chronic myeloid 
leukemia (CML) and of some acute lymphoblastic leukemias (ALL) 
Chronic myelogenous leukemia (CML) is a rare disease worldwide. However, a 
tremendous stream of basic and clinical advances over the last 45 years have kept CML 
at the forefront of scientific attention.  
The incidence of CML is approximately 1 to 2/100000.1 It accounts for 15-20% of all 
cases of leukemia in adults.1 The clinical hallmarks of CML are leukocytosis, a left shift 
in the differential count, and splenomegaly. If not effectively treated, CML follows a 
triphasic clinical course with an initial chronic phase (CP) that has an average duration 
of 5 years. During the chronic phase, there is gross expansion of the myeloid cell 
compartment, but the cells still retain the capacity to differentiate and function 
normally. Symptoms in this phase are generally mild and many patients are 
asymptomatic, being often diagnosed by routine blood sampling. Then the disease 
typically progresses to accelerated phase (AP), characterized by the appearance of more 
immature cells in the blood, frequent constitutional symptoms, and a less favorable 
response to therapy. The diagnostic criteria for accelerated phase are not universal, 
reflecting that disease progression from chronic to accelerated phase is a continuous 
process rather than a single step. Although the duration of accelerated phase varies from 
weeks to years, the disease inexorably progresses to the final stage of blast crisis (BC), 
that can be either myeloid or lymphoid in phenotype, where immature cells dominate 
and survival is measured in weeks to months. However, not all patients follow this 
triphasic course; some progress from the chronic phase directly to the blast phase and 
others die of complications in the chronic or accelerated phase.  
CML was first described as a distinct clinical entity in 1845 by the pathologists Bennet, 
Craigie, and Virchow. In 1960, a major clue to the cause of CML was provided by 
Nowell & Hungerford’s landmark discovery of the Philadelphia (Ph) chromosome, a 
minute acrocentric chromosome in the bone marrow cells of patients with CML (Figure 
1).2 This discovery was the first demonstration of a chromosomal rearrangement being 
consistently linked to a specific malignancy and sparked searches for associations of 
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additional chromosomal aberrations with other forms of cancer. In 1973, the Ph 
chromosome was recognized by Rowley and colleagues to result from the 
t(9;22)(q34;q11) reciprocal chromosomal translocation.3 By the mid-1980s, it became 
apparent that the t(9;22) translocation resulted in the juxtaposition, on the Ph 
chromosome, of the Abelson (ABL) proto-oncogene, located on the long arm of 
chromosome 9, to a gene of unknown function on the long arm of chromosome 22, 
which was called BCR for Breakpoint Cluster Region, since DNA breaks occurred in a 
relatively small genomic region.4 A new association of the Ph chromosome with B-cell 
acute lymphoblastic leukemia (B-ALL) was also discovered.5 Advances in chromosome 
mapping and molecular biology enabled the specific B-ALL Ph chromosome gene 
product with its chromosome breakpoints and mRNA sequence to be analyzed and 
compared with that of CML samples. Initial studies in Ph-positive (Ph+) B-ALL 
showed that a smaller 7.0 kb mRNA, as opposed to a CML Ph chromosome 8.5 kb 
mRNA product, was formed.6,7 Furthermore, the Bcr-Abl protein product in B-ALL 
samples was 185/190-kD (henceforth referred to as p185BCR-ABL) as opposed to the 210-
kD Bcr-Abl protein product (henceforth referred to as p210BCR-ABL) in CML samples.7,8 
The difference in the Ph chromosome gene product in B-ALL versus CML were due to 
differences within the BCR breakpoints.9 The translocation giving rise to the Ph 
chromosome in B-ALL was localized within the minor breakpoint cluster region (m-
bcr) in BCR,10-12 whereas in CML, the translocation site was within the major 
breakpoint cluster region (M-bcr) in BCR.4 Further studies showed a high but not 
absolute correlation between the p210BCR-ABL form and CML, and between p185BCR-ABL 
and B-ALL, questioning whether specific forms of Bcr-Abl may play a role in the 
aetiology of each leukaemia. With a frequency of 20–30%, patients harbouring the Ph 
chromosome constitute the largest cytogenetically defined subgroup among adult 
ALL.13 
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The Bcr-Abl fusion protein: the pathogenetic principle of CML and Ph+ ALL 
Of paramount importance was the discovery that the protein derived from the chimeric 
BCR-ABL gene had tyrosine kinase (TK) activity that was deregulated compared with 
normal Abl and correlated with its ability to transform cells to a malignant phenotype.14 
In vitro culture systems demonstrated that BCR-ABL can transform immature 
hematopoietic cells, some fibroblast cell lines, and hematopoietic cell lines rendering 
them growth factor independent.15-17 In addition, several groups reported that a CML-
like disease could be induced in mice transplanted with bone marrow infected with a 
BCR-ABL retrovirus.18-20 This proved the point that BCR-ABL is the causative agent and 
not just a marker of the disease.  
Both Bcr and Abl are multidomain proteins (reviewed in 21; Figure 2). The 
physiological function of Bcr is not well understood. The 160-kd Bcr protein is 
ubiquitously expressed. Several structural motifs can be delineated (Figure 2). The first 
N-terminal exon encodes a serine-threonine kinase. The only substrate of this kinase 
identified so far is Bap-1, a member of the 14-3-3 family of proteins. A coiled-coil 
domain at the N-terminus of Bcr allows dimer formation in vivo. The center of the 
molecule contains a region with dbl-like and pleckstrin-homology (PH) domains that 
stimulate the exchange of guanidine triphosphate (GTP) for guanidine diphosphate 
(GDP) on Rho guanidine exchange factors, which in turn may activate transcription 
factors such as NF-κB. The C-terminus has GTPase activity for Rac, a small GTPase of 
the Ras superfamily that regulates actin polymerization and the activity of an NADPH 
oxidase in phagocytic cells. In addition, Bcr can be phosphorylated on several tyrosine 
residues, especially tyrosine 177, which binds Grb-2, an important adapter molecule 
involved in the activation of the Ras pathway. Although these data argue for a role of 
Bcr in signal transduction, their true biologic relevance remains to be determined. The 
fact that BCR knockout mice are viable and the fact that an increased oxidative burst in 
neutrophils is thus far the only recognized defect probably reflect the redundancy of 
signaling pathways. 
The ABL gene is the human homologue of the v-abl oncogene carried by the Abelson 
murine leukemia virus (A-MuLV), and encodes a nonreceptor tyrosine kinase. Human 
Abl is an ubiquitously expressed 145-kd protein with 2 isoforms arising from alternative 
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splicing of the first exon. Several structural domains can be defined within the protein 
(Figure 2). Three SRC homology domains (SH1-SH3) are located toward the NH2 
terminus. The SH1 domain carries the tyrosine kinase function, whereas the SH2 and 
SH3 domains allow for interaction with other proteins. Proline-rich sequences in the 
center of the molecule can, in turn, interact with SH3 domains of other proteins, such as 
Crk. Toward the 3' end, nuclear localization signals and the DNA-binding and actin-
binding motifs are found. Several fairly diverse functions have been attributed to Abl. 
The normal Abl protein is implicated in a wide range of cellular processes, including 
regulation of cell growth and survival, oxidative stress and DNA-damage responses, 
actin dynamics and cell migration, transmission of information about the cellular 
environment through integrin signaling. To this purpose, Abl interacts with a large 
variety of cellular proteins – including signalling adaptors, other kinases, phosphatases, 
cell-cycle regulators, transcription factors and cytoskeletal proteins. Overall, it appears 
that the Abl protein serves a complex role as a cellular module that integrates signals 
from various extracellular and intracellular sources and that influences decisions in 
regard to cell cycle and apoptosis.  
Whereas the native c-Abl shuttles between the nucleus and the cytoplasm and has 
tightly regulated kinase activity, the Bcr-Abl counterpart is exclusively found in the 
cytoplasm and shows aberrant kinase activity. Under physiologic conditions, the SH3 
domain and the more 5' regions of Abl protein appear to play a critical role in kinase 
inhibition and both cis- and trans-acting mechanisms have been proposed to mediate this 
inhibition. Loss of 5’ regions of Abl, together with fusion of Bcr sequences 
encompassing the oligomerization domain, abrogate the physiologic suppression of the 
kinase (Figure 3). 
Two major mechanisms have been implicated in the malignant transformation by Bcr-
Abl, namely a) altered adhesion to stroma cells and extracellular matrix, and b) 
constitutively active mitogenic signaling and reduced apoptosis. 
a) Altered adhesion properties - CML progenitor cells exhibit decreased adhesion 
to bone marrow stroma cells and extracellular matrix. In this scenario, adhesion 
to stroma negatively regulates cell proliferation, and CML cells escape this 
regulation by virtue of their perturbed adhesion properties. Interferon-α (IFN-α), 
an active therapeutic agent in CML, appears to reverse the adhesion defect. β-
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integrins play an important role in the interaction between stroma and progenitor 
cells, and CML cells have been found to express an adhesion-inhibitory variant 
of β1 integrin that is not found in normal progenitors. On binding to their 
receptors, integrins are capable of initiating normal signal transduction from 
outside to inside; it is thus conceivable that the transfer of signals that normally 
inhibit proliferation is impaired in CML cells. Because Abl has been implicated 
in the intracellular transduction of such signals, this process may be further 
disturbed by the presence of a large pool of Bcr-Abl protein in the cytoplasm. 
Furthermore, Crkl, one of the most prominent downstream tyrosine-
phosphorylated proteins in BCR-ABL-transformed cells, is involved in the 
regulation of cellular motility and in integrin-mediated cell adhesion by 
association with other proteins such as paxillin and the focal adhesion kinase 
Fak. 
b) Activation of mitogenic signaling and inhibition of apoptosis – multiple signals 
initiated by Bcr-Abl have proliferative and anti-apoptotic effects that are 
frequently difficult to separate, in line with the concept that a proliferative signal 
leads to apoptosis unless it is counterbalanced by an anti-apoptotic signal. Thus, 
Bcr-Abl may shift the balance toward the inhibition of apoptosis while 
simultaneously providing a proliferative stimulus. Several cellular cascades 
activated by Bcr-Abl are involved. They include: 
- Ras and the MAP kinase pathway: autophosphorylation of Bcr tyrosine 
177 provides a docking site for the adapter molecule Grb-2. Grb-2, after 
binding to the Sos protein, stabilizes Ras in its active, GTP-bound form. 
Two other adapter molecules which are known to be substrates of Bcr-
Abl-mediated phosphorylation, Shc and Crkl, can also activate Ras. 
Circumstantial evidence that Ras activation is important for the 
pathogenesis of Ph+ leukemias comes from the observation that 
activating mutations are uncommon, even in advanced phases of the 
disease, unlike in most other tumors. This implies that the Ras pathway is 
constitutively active, and no further activating mutations are required. 
Activation of Ras and subsequent recruitment of the serine-threonine 
kinase Raf to the cell membrane initiates a signaling cascade through the 
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serine-threonine kinases Mek1/Mek2 and Erk, which ultimately leads to 
the activation of gene transcription. 
- Stat pathway: Bcr-Abl can directly phosphorylate Stat1 and Stat5 
transcription factors. Although Stat5 has pleiotropic physiologic 
functions, its effect in BCR-ABL-transformed cells appears to be 
primarily anti-apoptotic and involves transcriptional activation of Bcl-xL. 
- PI3K pathway: Bcr-Abl forms multimeric complexes with phosphatidyl-
inositol-3-kinase (PI3K), Cbl, and the adapter molecules Crk and Crkl, in 
which PI3K is activated. The next relevant substrate in this cascade 
appears to be the serine-threonine kinase Akt. This kinase had previously 
been implicated in anti-apoptotic signaling. A recent report placed Akt in 
the downstream cascade of the IL-3 receptor and identified the pro-
apoptotic protein Bad as a key substrate of Akt. Phosphorylated Bad is 
inactive because it is no longer able to bind anti-apoptotic proteins such 
as BclXL and it is trapped by cytoplasmic 14-3-3 proteins. Altogether this 
indicates that Bcr-Abl might be able to mimic the physiologic IL-3 
survival signal in a PI3K-dependent manner. Ship and Ship-2, 2 inositol 
phosphatases with somewhat different specificities, are activated in 
response to growth factor signals and by Bcr-Abl. Thus, Bcr-Abl appears 
to have a profound effect on phosphoinositol metabolism, which might 
again shift the balance to a pattern similar to physiologic growth factor 
stimulation. 
A detailed overview of the cellular molecules involved in Bcr-Abl transforming 
signaling is shown in Figure 4. 
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The Bcr-Abl inhibitor imatinib mesylate: the first example of targeted 
molecular therapy 
The only known cure for CML is allogeneic stem cell transplantation in the chronic 
phase of the disease. This therapy has demonstrated long term disease free survival of 
50–80% after 3–10 years of follow-up.22,23 Unfortunately, this treatment is not an option 
for the majority of patients due to the lack of an HLA-matched related donor or the risk 
of transplantation-related mortality. Introduced at the beginning of the 80s, IFN-α, 
alone or in combination with cytarabine, has been the standard treatment for patients 
unable to undergo allogeneic stem cell transplantation until the introduction of tyrosine 
kinase inhibitors (TKIs). While this therapy is able to induce cytogenetic remissions in 
up to 50% of CML patients when treated in CP, it is associated with a range of adverse 
effects.24-29 
The considerable wealth of knowledge on the molecular and cell biology of CML 
gathered over the past twenty years of research created the essential platform for 
molecular targeted therapies to be engineered. It soon became clear that the Bcr-Abl 
oncoprotein itself is the ideal target, since (a) it has a central role in CML pathogenesis, 
and (b) it is not expressed by normal cells. Furthermore, the dissection of the signal 
transduction pathways affected by the deregulated kinase activity of Bcr-Abl provided 
information on additional or alternative signalling steps that could be interrupted in an 
attempt to block the leukemogenic process.  
The first breakthrough in the treatment of CML has been the development of imatinib 
mesylate. Imatinib mesylate, originally designated signal transduction inhibitor 571 
(STI571), arose from a time-consuming process of random screening of large numbers 
of compounds created using the structure of the ATP-binding site. Imatinib is a 2-
phenyl-amino-pyrimidine and it emerged as one of the most potent substances inhibiting 
the Abl protein. It also inhibits other kinases, predominantly those related to platelet-
derived growth factor receptors and c-Kit. The catalytic domains of eukaryotic 
serine/threonine and tyrosine kinases have a highly conserved bilobed structure. The 
NH2-terminal lobe (N-lobe) contains a β-sheet and a conserved α-helix (helix C), 
whereas the COOH-lobe (C-lobe) is helical. In the interface between the two lobes there 
is a cleft where a series of highly conserved residues form the ATP binding and 
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catalytic sites.30 The activation state of kinases is dependent on the position of the 
activation loop, a portion of the C-lobe, which in Abl comprises amino acid residues 
381–402. In active kinases, the activation-loop is in an “open” conformation, because it 
swings away from the catalytic center of the kinase. The three NH2-terminal residues of 
the activation-loop (amino acids 381–383) contain a strictly conserved DFG (aspartate-
phenylalanine-glycine) motif, which is crucial for catalytic activity. Aspartate 381 is 
able to bind Mg2+, which in turn coordinates the phosphate groups of ATP. The COOH-
terminal portion of the activation-loop serves as a platform for substrate binding. 
Although the conformation of the activation loop is highly conserved in kinases when 
they are in the active, open conformation, there are considerable differences between 
their inactive (closed) conformations. Kinases are activated by phosphorylation of key 
serine/threonine or tyrosine residues within the activation-loop. In the case of Abl, 
tyrosine 393 is phosphorylated and points away from the center of the kinase, allowing 
substrates to bind. In the inactive state of Abl, tyrosine 393 is unphosphorylated and 
points toward the center of the kinase, mimicking a substrate by forming a hydrogen 
bond with asparagines 363. In this conformation, the mouth of the kinase is occluded, 
preventing substrate binding.30,31  
Co-crystal structure analysis revealed that imatinib selectively binds to a distorted 
inactive conformation of the Abl kinase domain (KD) through an induced-fit 
mechanism.31-33 Remarkably, the potency of imatinib towards constitutively active Bcr-
Abl implies a dynamic equilibrium from which imatinib can trap the deregulated Bcr-
Abl oncoprotein when it transits through its inactive conformation (Figure 5). This 
mode of binding is potentially an Achilles' heel for imatinib compared with other small-
molecule kinase inhibitors that are effective against the catalytically active kinase 
conformation. 
Functionally, imatinib acts by revoking the effects of the Bcr-Abl oncoprotein through 
inhibition of Bcr-Abl autophosphorylation and substrate phosphorylation, thus blocking 
proliferation and inducing apoptosis.34-36 Its favourable oral bioavailability profile and 
lack of significant toxicity in animal models led to the design of large phase I and II 
trials to test its safety and efficacy in humans (Table 1). Thus, in the spring of 1998, a 
phase I clinical trial was initiated in the United States in which patients with CML in CP 
who had failed IFN-α were treated with imatinib in increasing doses, from 25 mg/d up 
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to 1000 mg/d. Adverse side effects from imatinib were minimal, with the most common 
being nausea, myalgias, edema, and diarrhea. In fact, a maximum tolerated dose could 
not be identified as a result of these studies, despite a trend for a higher frequency of 
grade 3 to 4 adverse events at doses of 750 mg/d or higher. Complete hematologic 
responses (CHR) were seen in 53 of 54 patients who were treated with imatinib in doses 
of 300 mg/d or more. Of these 54 patients, cytogenetic responses occurred in 29. 
Seventeen patients achieved major cytogenetic responses (MCgR) and 7 had a complete 
cytogenetic remission (CCgR). These results were truly remarkable for this group of 
patients. For this reason, a second phase I trial was performed in 58 patients with 
myeloid (38 patients) or lymphoid (20 patients, including Ph+ ALL) BC of CML. These 
patients received doses ranging from 300 to 1000 mg/d. Fifty-five percent (21/38) of the 
patients with myeloid BC demonstrated responses; 4 of these 21 patients had a CHR. 
Seventy percent (14/20) of the patients with lymphoid BC or Ph+ ALL had a response, 
including 4 who had a CHR. Seven patients with myeloid BC were continuing to 
receive treatment at the time of the report. All but one of the patients with lymphoid BC 
or Ph+ ALL who responded had relapsed. Subsequently, three large, multinational 
phase II studies were initiated in late-CP, AP and myBC patients (Table 1). Imatinib 
was administered at a dose of 400 mg/d in late-CP patients and at doses of 400 or 600 
mg/d in AP and BC patients. The results of these studies indicated that the rate of both 
hematologic and cytogenetic responses increased as the treatment was started earlier in 
the course of the disease. In the advanced phase studies, a dose of 600 mg/d was 
superior to 400 mg/d in terms of response rates and time to progression. Importantly, 
landmark analyses indicated that the achievement of a hematologic and/or cytogenetic 
response was associated with improved survival and progression-free survival. Adverse 
events were again mild in the setting of CP patients. Neutropenias and 
thrombocytopenias were more common in patients with advanced disease, suggesting 
that hematologic toxicity may be related more to an underlying compromised bone 
marrow reserve rather than to the drug itself.  
Taken together, these results established imatinib as a safe and effective therapy for all 
stages of CML and were the basis for the initial marketing approval by the Food and 
Drug Administration (FDA) on May, 2001, i.e., after less than 3 years after the start of 
the first phase I study. On the same month, imatinib made the cover of Time as “the 
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magic bullet” to cure cancer. These encouraging results led to a large randomized trial 
comparing first-line therapy with imatinib at 400 mg/d versus standard IFN-α in 
combination with low-dose cytarabine in patients with newly diagnosed CP CML – the 
International Randomized Trial of Interferon and STI571 (IRIS). One thousand one 
hundred and six patients were enrolled – 553 in each arm. Crossover to the alternative 
therapy was allowed in case of failure to achieve a CHR at 6 months, failure to achieve 
a MCgR at 12 months, loss of response, intolerance. Indeed, 359 (65%) patients in the 
IFN-α plus cytarabine arm crossed over to imatinib (as against 14 [2.5%] patients in the 
imatinib arm), mainly because of intolerance, making the comparison between the two 
treatments formally impossible. The initial report of this study,37 with a median follow-
up of 19 months, showed that the estimated rate of MCgR at 18 months was 87% in the 
imatinib arm and 35% in the IFN-α plus cytarabine arm (P<.001). CCgR was achieved 
in 76% of patients who were given imatinib, as against 15% of patients who were given 
IFN-α plus cytarabine (P<.001). The five-year-updated results of this trial have recently 
been published,38 confirming stability of responses to imatinib (with the quality of 
hematologic, cytogenetic and molecular responses even improved over time) and 
decreasing incidence of serious adverse events. At 60 months, for patients treated with 
imatinib the estimated CHR rate is 98%,  the MCgR rate is 85%, the CCgR rate is 92%. 
The estimated rate of progression to AP/BC has decreased from 1.5% and 2.8% in the 
first and second year of treatment, respectively, to 1.6%, 0.9%, 0.6% in the third, fourth 
and fifth year, respectively. 
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Resistance to imatinib: incidence and mechanisms 
Shortly after the encouraging results of the first clinical trials were announced there 
came the first of reports of resistant cases, which represented the proof of principle that 
the Bcr-Abl-positive clone may evolve to evade Bcr-Abl inhibition. 
Primary resistance to imatinib, defined as an inability to achieve landmark response, is 
comprised of the 2% of patients who fail to achieve hematologic response (HR) and 8-
13% who fail to achieve MCgR or CCgR using early CP CML treated with imatinib at 
diagnosis as a benchmark.38 Secondary resistance includes patients who achieve but 
subsequently lose relevant response – loss of cytogenetic or hematologic response and 
progression from chronic to advanced-stage disease. Again per the benchmark IRIS trial 
of CP patients with primary imatinib therapy,38 the rate of all progression events, 
including cytogenetic and hematologic relapse within CP and transformation to 
advanced phase, is 18% after a median of 5 years. However, such events appear to be 
most evident in the first 3 years of treatment in the IRIS trial, where progression to 
advanced phases of disease averaged 2% per year and progression within CP 5% per 
year; year 4 then showed diminished rates and in year 5 both risks are less than 1%. For 
CP patients with intolerance or failure during prior IFN-α, early, significant response to 
imatinib predicts for maximal protection from progression; after 5 years of follow-up, 
69% of patients overall have remained free of progression; however, those achieving 
CCgR or MCgR by 3 months are 94% and 87% free from progression to AP/BC, 
respectively, versus only 55% for the remaining patients.39 The relapse rate in this 
cohort appeared to be fixed at approximately 7% per year.39 Lastly, for patients with 
advanced disease treated with imatinib as salvage therapy, rates of resistance and 
relapsing disease is dramatically higher, occurring in 75% or more of AP patients and 
95% of myeloid BC patients.40 
Early investigations in advanced phase CML cases who had relapsed on imatinib 
therapy had first indicated either BCR-ABL gene amplification or a mutation at residue 
315 in the Abl KD as the determinants of Bcr-Abl reactivation within the leukemic 
clone. On binding, the hydroxyl group of threonine 315 of Bcr-Abl, the so-called 
'gatekeeper' residue, forms a hydrogen bond with imatinib, and the side chain present at 
position 315 also sterically controls the binding of the inhibitor to hydrophobic regions 
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adjacent to the ATP-binding site.30,31 The substitution of threonine with a bulkier and 
more hydrophobic isoleucine was shown to eliminate this hydrogen bond required for 
high-affinity inhibitor binding and to create a steric hindrance interfering with imatinib 
placement within the ATP-binding site.30,41 Importantly, although threonine 315 is 
essential for imatinib, this is not the case for ATP binding, which does not depend on 
the accessibility of the same hydrophobic cavity and is therefore not affected by the 
incorporation of a bulky isoleucine side chain. The individual structural requirements of 
ATP and imatinib mean that the catalytic activity, and therefore the tumour-promoting 
function, is preserved in the imatinib-insensitive T315I mutant. A strikingly identical 
amino acid substitution was later shown to occur at homologous positions in the KD of 
c-kit (T670I) and PDGFRα (T674I) kinases in imatinib-resistant gastrointestinal stromal 
tumors and hypereosinophilic syndromes, respectively,42,43 further highlighting the 
central role of this highly-conserved ‘gatekeeper’ threonine in controlling the 
accessibility of the ATP-binding pocket to inhibitors. 
The vast number of mutation reports since published33,44-50 has led to an exponential 
increase in the number and type of amino acid substitutions found in CML patients who 
either lost or did not achieve response to imatinib treatment (a comprehensive list may 
be found in Table 2). c-Abl has 3 Src homology domains, including SH3, which is a 
negative regulator of kinase activity; SH2, which binds peptides that contain 
phosphotyrosine; and SH1 – the KD – which encodes for catalytic function. At the NH2-
terminal end of the Abl kinase is a highly conserved nucleotide phosphate binding 
domain for adenosine triphosphate, which is known as the P-loop. At the COOH-
terminal end of the molecule is a flexible activation loop that is essential for the control 
of catalytic activity and changes conformation depending on whether the molecule is in 
the inactive or active state. Between these 2 loops is the catalytic site of the molecule, 
which resides in a cleft where imatinib and other small molecule tyrosine kinase 
inhibitors bind. Abl shifts between an inactive or a closed conformation and a 
catalytically active or open conformation, and this shift from an inactive to active state 
appears to be regulated by the kinase itself in a process known as ‘‘autoinhibition.’’ In 
the inactive state, the activation loop just described is folded inward toward the catalytic 
site, and in the active state, this activation loop flips away from the catalytic region. 
Thus, it can act as a support for substrate binding. Mutations disrupt imatinib binding by 
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affecting critical residues implicated in direct contact with the inhibitor or preventing 
Bcr-Abl from effectively adopting the specific inactive conformation which imatinib 
binds.  
The majority of these Bcr-Abl mutant forms are now well characterized in terms of the 
extent to which they confer insensitivity to imatinib (Table 2).33,44,51 Indeed, while some 
mutations (T315I and mutations falling within the P-loop region, i.e., G250E, Y253F/H 
and E255K/V) confer a highly resistant phenotype, other are associated with a relatively 
modest increase in imatinib IC50 and might therefore be overcome by a dose increase. 
Controversy remains over the point in time when such mutations are acquired. In 
anecdoctical reports, the same mutant clone observed at relapse was retrospectively 
traced back to the sample archived prior to imatinib start,45,52 speaking to the theory of 
outgrowth with selection pressure. However, this is not a universal finding – a study on 
a large, unselected cohort of imatinib-naïve patients has recently demonstrated that in 
some cases different mutant clones may observed before therapy and at relapse.53 
Beyond the “signature” of a KD mutation (the particular amino acid substitution and 
kinase region being predictive), the “fitness” of mutant clones – their ability to sustain 
long-term proliferation with a relative advantage over Ph-negative clones or wild type 
Bcr-Abl – is most relevant to risk. While it is accepted that expansion of a Ph+ CML 
clone bearing an Abl KD mutation may be associated with resistance to imatinib, the 
fact that mutations may be identified prior to imatinib exposure and do not strictly 
correlate with clinical resistance suggests a role for additional mechanisms to trigger 
outgrowth of mutants, or that genesis of mutant clones reflects greater genetic 
instability. Cytogenetic clonal evolution has indeed been linked to mutation detection 
prior to imatinib. screening for mutations prior to imatinib and for those with stable 
minimal residual disease are worthless because they may yield misleading information.  
Similarly, rare Ph+ cells harbouring mutations have been detected in 12 to 38% of 
patients who are in stable CCgR on imatinib.54,55 However, in some cases they turned 
out to be only a transient finding – the mutated clone did not outgrow and did not lead 
to clinical relapse. In other cases, the patient actually relapsed, but with evidence of a 
different mutated clone. The cases in which outgrowth of the mutated clone and 
subsequent relapse were indeed observed were all cases in which a significant rise in 
BCR-ABL transcript levels had accompanied detection of the mutation. Therefore, 
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monitoring responding patients with supersensitive techniques for the emergence of KD 
mutations is worthless, too, unless a significant rise in BCR-ABL transcript levels is 
observed.  
Besides Abl KD mutations, other mechanisms of resistance exist or have been 
hypothesized on the basis of in vitro observations in cell lines selected for imatinib 
resistance (Figure 6). Drug efflux, for example, has often been implicated in resistance 
to chemotherapeutics. In one study, investigators reported increases in the multidrug 
resistance (ABCB1; MDR1) gene that encodes the P-glycoprotein (Pgp) in a subclone 
of a resistant human leukemia cell line (Lama-84R) derived by growing the cells in 
increasing concentrations of imatinib.21 Increased expression of Pgp could potentially 
reduce or even deplete intracellular levels of imatinib, thereby reactivating Bcr-Abl 
signaling. While some in vitro models have supported this finding, others have 
demonstrated that overexpression of Pgp in K562, a human CML cell line, does not 
confer resistance to imatinib.56-59 More recently, another multidrug transporter, ABCG2 
(BCRP), has been implicated in imatinib transport and resistance.56,60 Reduced drug 
influx has also been hypothesized to play a role in imatinib resistance. Lower baseline 
values of the mRNA encoding the drug transporter hOCT161 have recently been 
reported in CP patients with primary cytogenetic resistance to imatinib.62 Other studies 
showed that imatinib may be sequestered in the plasma by drug-binding proteins. The 
plasma protein alpha-1 acid glycoprotein (AGP) has been shown to bind imatinib at 
physiologic concentrations in vitro and block the ability of imatinib to inhibit Bcr-Abl 
kinase activity.63 However, whether drug influx/efflux and/or plasma sequestration 
represent major mechanisms of resistance to imatinib in CML still remains 
controversial. 
Bcr-Abl-independent mechanisms have also been hypothesized. In such a scenario, the 
leukemia cells no longer rely on Bcr-Abl for their proliferative drive, but rather rely on 
alternate oncogenic signalling pathways which allow the leukemic clone to bypass Bcr-
Abl inhibition by imatinib. In an in vitro model of resistance, one group demonstrated 
that an imatinib-resistant K562 subline was sensitive to inhibition of the Src-family 
kinases Lyn and Hck, and that these kinases were up-regulated in patients who acquired 
resistance during the course of imatinib therapy.64,65 These observations are supported 
by precedent finding that Src family kinases may operate downstream of Bcr-Abl in 
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CML. The same group extended these observations to continuous cell lines derived 
from imatinib-resistant patients,66 but there is little current evidence that Src activation 
is responsible for true clinical resistance to imatinib in patients.  
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Therapeutic strategies to address imatinib-resistant disease 
Despite the excellent clinical results obtained with the introduction of imatinib, it was 
soon recognized that there was still a need to improve on the treatment of Ph+ 
leukemias. Relapse of the disease due to the emergence of resistance to imatinib is a 
major problem. In addition, most patients who are in CCgR on imatinib still do harbour 
residual Bcr-Abl-positive cells – this is known as “residual disease” and can be detected 
by sensitive assays like nested reverse transcription-polymerase chain reaction (RT-
PCR).  
These two obstacles have fostered intensive efforts aiming at the development of 
alternative inhibitors or alternative inhibitory strategies. Several approaches can be 
envisioned and are currently being explored.  
High-dose imatinib (800 mg/d) early in disease continues to be studied in comparison to 
standard dose, with randomized trials ongoing and data forthcoming; further update of 
previously published single center experiences now shows similar ultimate depth of 
response for both 400 and 800 mg dosing, yet increased rapidity of response and also 
potentially lower risk of progression for higher dose imatinib.67 It still remains to be 
assessed whether increased toxicity of 800 mg dosing may be limiting. 
More potent and specific inhibitors capable of binding Bcr-Abl with less stringent 
conformational requirements have been rationally designed and some of them have 
already advanced to clinical trials. They include dasatinib (BMS-354825), nilotinib 
(AMN-107) and bosutinib (SKI-606).  
Dasatinib (Figure 7) is a thiazolylamino-pyrimidine emerged from a programme 
directed towards immunosuppressant drugs and, in addition to inhibiting the Src family 
kinases Fyn, Lck, Src and Yes, it potently inhibits Abl, c-Kit, PDGFRβ, EPHA2, HER1 
and p38 MAP kinases.68 Dasatinib exhibited ~300-fold higher potency than imatinib 
against Bcr-Abl and was shown to retain activity in vitro against most of the clinically 
relevant imatinib-resistant Bcr-Abl mutant forms, with the notable exception of the 
T315I.69,70 Recent co-crystal studies have indicated that dasatinib, unlike imatinib, is 
able to recognize multiple conformations of Bcr-Abl.71  
Nilotinib is a phenylamino-pyrimidine derivative structurally related to imatinib. It was 
rationally designed based upon the crystal structure of imatinib-Abl complexes together 
with medical chemistry paradigms for drug discovery. As a Bcr-Abl kinase inhibitor, 
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AMN107 is in the range of 20- to 30-fold more potent than imatinib and is highly 
selective for Bcr-Abl (rank order of potency Bcr-Abl>PDGFR>c-Kit), whereas the 
latter is most potent against PDGFR kinases (rank order of potency PDGFR>c-Kit>Bcr-
Abl). Nilotinib binds the inactive conformation of Bcr-Abl, as imatinib does, but with a 
less stringent requirement in the absolute shape and charge of the binding surface of the 
protein compared to imatinib. For this reason, it was found to maintain potency against 
both Bcr-Abl phosphorylation and cell viability in cell lines expressing several imatinib-
resistant mutant forms, although, again like dasatinib, with the exception of T315I.70 
Dasatinib and nilotinib were brought to clinical trials nearly simultaneously. Phase I 
trials in CML for both agents were recently reported simultaneously in paired 
articles.72,73 Phase I studies for both agents included patients with resistant CP disease, 
with slightly different inclusion criteria (mainly allowance for imatinib intolerant 
patients [20% of the total] in the dasatinib study and patients with cytogenetic resistance 
only [i.e., still in CHR] in the nilotinib trial). The rate of CHR was identical for both at 
92%, as was CCgR at 35%, with an additional 10% of patients on dasatinib achieving 
partial cytogenetic response, bringing the totals for MCgR to 45% for dasatinib and 
35% for nilotinib. No dose-limiting toxicity was observed for dasatinib, with a range of 
15-240 mg per day administered; for nilotinib, dosing at 600 mg BID was limiting, with 
associated liver (predominantly grade 3 indirect bilirubin and transaminase) and 
pancreatic enzyme elevations (including grade 2 pancreatitis), as well as one grade 3 
subdural hematoma. Pleural effusions deemed therapy related were observed in 15 of 84 
dasatinib treated patients overall in phase I and were treated with diuretics and/or 
drainage. Other higher-grade toxicity from dasatinib included edema, headache, and 
elevated transaminase levels. Myelosuppression was observed beyond the level seen 
with imatinib for both agents, and was more pronounced with dasatinib; however, 
comparison may be difficult due to the fact that patients with imatinib failure and 
intolerance may be at greater risk due to longer disease duration or other factors. 
Activity was seen for advanced phases of CML and Ph+ ALL with both agents in phase 
I. Phase II studies for dasatinib in all phases of CML and Ph+ ALL have been 
reported74-76 and supported rapid FDA approval of the compound (named Sprycel) on 
29/6/06 for both indications at the recommended dose of 70 mg BID. In the phase II 
trial of dasatinib in CP CML, 60% of patients required dose reductions over time for 
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toxicity and the median dose was closer to 100 mg per day; ongoing trials continue to 
explore dosing options for dasatinib, including varying total dose and QD versus BID 
dosing.77,78 Early phase II data has been presented for nilotinib,79-81 expanding 
experience with the 400 mg BID dosing. Results for both agents in CP remain 
impressive, with the majority of patients achieving sustained HR and approximately 
one-half MCgR and one-third CCgR. Advanced phase results show more limited 
salvage capability for both agents, particularly for the Ph+ acute leukemias, with early 
relapse common; in AP, with both agents, a subset of responders remains fairly durable, 
albeit with limited follow-up. A randomized trial of dasatinib (70 mg BID) versus 
imatinib 800 mg/d for patients with hematologic or cytogenetic resistance to lower dose 
of imatinib (400-600 mg/d)82 reported early improvement in CCgR rate for dasatinib 
over high dose imatinib. 
Bosutinib (SKI-606) is an anilino-quinolinecarbonitrile that, like dasatinib, belongs to 
the class of dual Src/Abl inihibitors.83 Bosutinib proved to be an active inhibitor of Bcr-
Abl in several CML cell lines and transfectants, with IC50 values in the low nanomolar 
range, 1 to 2 logs lower than those obtained with imatinib.84,85 Bosutinib retained 
activity in imatinib-resistant cell lines displaying BCR-ABL gene amplification as well 
as in BaF3 cell expressing Y253F-, E255K and D276G-Bcr-Abl.85 Again, the T315I 
was highly resistant. Phase I/II trials are ongoing.86 
The lack of efficacy of these second-generation Bcr-Abl inhibitors, as well as of several 
additional compounds that have been sinthesized and tested pre-clinically (reviewed in 
87), against the T315I mutation represents a major concern. For T315I-positive patients, 
however, effective therapeutic approaches might soon be available. To expedite the 
identification and the availability of second-line strategies overcoming resistance 
induced by the T315I mutation, three approaches are successfully being pursued. The 
first is to design inhibitors binding regions of Bcr-Abl other than the ATP binding 
pocket. This is the case of ON012380, a substrate-competitive inhibitor which exhibited 
activity at low nanomolar concentrations against wild-type Bcr-Abl and all imatinib-
resistant Bcr–Abl mutants, including the T315I, both in biochemical and in cellular 
assays.88 Unfortunately, ON012380 has not yet entered clinical trials where it must 
prove its safety in use as well as its in vivo efficacy in achieving remission and 
preventing resistance. A second approach is to test targeted agents with a different mode 
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of action, i.e., molecules which target Bcr-Abl stability or a Bcr-Abl downstream signal 
transducer, alone or in combination with imatinib (or another Bcr-Abl kinase inhibitor). 
Very recently, the histone-deacetylase inhibitor LBH589 has been documented to 
deplete Bcr-Abl and induce growth arrest and apoptosis in cells expressing T315I-Bcr-
Abl, both when administered alone and, even more effectively, when administered in 
combination with nilotinib.89 Safety and tolerability of the orally-available LBH589B 
are being assessed in a phase I trial in patients with advanced solid tumors and 
cutaneous T cell lymphomas,90 and phase II trials in CML are being planned. Similar 
encouraging results have been obtained with another histone-deacetylase inhibitor, 
vorinostat (suberoylanilide hydroxamic acid, SAHA), alone or in combination with 
dasatinib.91 Combinations of vorinostat with various conventional agents are currently 
being evaluated in several malignant conditions (http://www.clinicaltrials.gov). By 
inhibiting histone deacetylase 6 and inducing acetylation of heat shock protein 90 
(hsp90), LBH589 and vorinostat have been shown to attenuate the ATP-binding and 
chaperone function of hsp90.92 This leads to polyubiquitylation, proteasomal 
degradation and depletion of hsp90-client proteins, including Bcr-Abl itself and its 
downstream effectors c-Raf and AKT. Moreover, vorinostat and LBH589 are known to 
induce apoptosis in human leukemia cells via a general mechanism of accumulation of 
pro-apoptotic proteins (Bax, Bim) coupled with depletion of anti-apoptotic factors (Bcl-
2, Bcl-XL, survivin), which may enhance the effects of Bcr-Abl inhibitors.93  
A third, intriguing approach is to explore the possibility of whether molecules that have 
been developed as inhibitors for other protein kinases and are already undergoing 
clinical trials, might include the T315I-Bcr-Abl among their “off-targets”. One such 
screening has recently disclosed that the p38 inhibitor BIRB-796 and the aurora kinase 
inhibitor MK-0457 (VX-680) are both capable of binding T315I-Bcr-Abl.94 BIRB-796, 
currently being evaluated in clinical trials for inflammatory bowel disease, binds T315I-
Bcr-Abl with good affinity (Kd=40nM), but has significantly weaker affinity for wild-
type and other imatinib-resistant forms of Abl (Kd values >1µΜ). MK-0457 (VX-680) 
is able to bind both wild-type and mutated Bcr-Abl and has been reported to inhibit 
T315I-Bcr-Abl at low micromolar concentrations in primary patient cells.95 
Additionally, recent co-crystal studies have shown that this Y-shaped molecule engages 
the Abl KD in such a way that a close encounter with the gatekeeper residue is avoided, 
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explaining why the compound is able to accommodate the substitution of threonine with 
isoleucine without any significant decrease in binding affinity.95 MK-0457 is currently 
undergoing a phase I trial in leukemias, including advanced phase CML and Ph+ ALL, 
and encouraging responses in patients harbouring the T315I mutation have been 
reported.96,97 A phase II trial in the specific setting of T315I-positive Ph+ leukemias is 
forthcoming.  
It will be interesting to assess whether more potent Bcr-Abl inhibitors administered 
first-line might prove valuable in sinking the pool of residual leukemic cells from which 
mutant clones may emerge. Clinical trials are being planned in order to evaluate this 
premise. In addition, combination of inhibitors with a non-overlapping spectrum of 
resistance mutations or, even better, with non-overlapping mode of action, have been 
predicted to be particularly promising98 and their assessment in clinical trials is also 
warranted. These strategies could be particularly suitable for the treatment of Ph+ ALL, 
where high genomic instability rapidly drives the emergence and selection of T315I and 
other highly resistant Abl KD mutations. 
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Tables 
 
 
 
 
 
 
 
 
 
Study Indication Patients (n) Enrollment period 
Phase I studies    
        Druker et al99 Late-CP 83 Jun 1998-May 2000 
        Druker et al100 BC, ALL 58 Apr 1999-Mar 2000 
Phase II studies    
        Sawyers et al101 Myeloid BC 260 Aug 1999-Jun 2000 
        Talpaz et al102 AP 235 Aug 1999-Mar 2000 
        Kantarjian et al103 Late-CP 532 Dec 1999-May 2000 
        Ottmann et al104 Lymphoid BC, ALL 56 Sep1999-May 2000 
Phase III study    
        IRIS38 Early-CP 1106 Jun 2000-Jun 2001 
Expanded access program    
       Protocol 113 Late-CP 4131 May 2000-Sep 2002 
       Protocol 114 AP 3093 May 2000-Sep 2002 
       Protocol 115 BC, ALL 1068 May 2000-Sep 2002 
 
Table 1 – Outline of the clinical development program of imatinib in Ph+ leukemias. 
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imatinib IC50 (nM)  Bcr-Abl Biochemical Cellular 
 Wild-type 300 260-500 
 M244V 380 2000 
L248V n.a. 1500 
G250E 1000 1350-3900 
Q252H n.a. 1200-2800 
Y253F* >5000 3475 
Y253H* >5000 >10000 
E255K 2800 4400-8400 
P-
lo
op
 
E255V >5000 >5000 
 D276G n.a. 1500 
 T277A n.a. n.a. 
 F311L 775 480 
 F311I n.a. n.a. 
 T315I* >5000 >10000 
 F317L* 900 810-1500 
 M343T n.a. n.a. 
M351T 820 930 
M351V n.a. n.a. 
E355D n.a. n.a. 
E355G n.a. 400 C
at
al
yt
ic
 
do
m
ai
n 
F359V* 4700 1200 
V379I 800 1630 
A380T* 340 2450 
F382L n.a. n.a. 
L387M 1500 1000 
L387F n.a. 1100 
H396P 340-800 850-4200 A
ct
iv
at
io
n 
lo
op
 
H396R 1950 1750 
 S417Y n.a. n.a. 
 E459K n.a. n.a. 
 F486S 1230 2800 
 
Table 2 – IC50 values of Bcr-Abl mutations observed in patients who are resistant to imatinib. 
Shaded boxes highlight residues belonging to the P-loop, catalytic domain and activation loop, as 
indicated. Residues marked with an asterisk (*) represent imatinib contact sites. IC50 is the concentration 
that inhibits by 50% the biochemical kinase activity of Bcr-Abl and suppresses by 50% the growth of Ph+ 
cell lines. n.a., not available. 
 23
Figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Representative karyotype from a CML patient showing the Philadelphia 
chromosome. The t(9;22) chromosomal translocation results in the formation of a shortened 
chromosome 22 (the Philadelphia chromosome) and a longer chromosome 9. 
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Figure 2 – Structure of the c-Bcr, c-Abl and Bcr-Abl proteins. c-Bcr comprises an 
oligomerization domain, a domain thought to mediate binding to SH2-domain-containing proteins, a 
serine/threonine kinase domain, a region with homology to Rho guanine-nucleotide-exchange factor 
(Rho-GEF), a region thought to facilitate calcium-dependent lipid binding (CaLB) and a region 
showing homology to Rac GTPase activating protein (Rac-GAP). The main phosphorylation site of 
Bcr (Tyr 177) is indicated. c-Abl comprises an SH3 and SH2 domain, an SH1 tyrosine kinase 
domain, several proline-rich domains (P), a nuclear localization signal (NLS), several DNA-binding 
domains (DNA BD) and an actin-binding domain. The Bcr-Abl fusion protein comprises the first 
four domains of c-Bcr and all the c-Abl domains except the N-terminal SH3 domain. 
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Figure 3 – Mechanisms responsible for Bcr-Abl-induced malignant transformation in Ph+ 
cells. As a consequence of the t(9;22) translocation, the regulatory regions at the NH2-terminus of c-
Abl are lost and replaced by the oligomerization domain of c-Bcr. This induces constitutive 
dimerization and autophosphorylation of Bcr-Abl, whose uncontrolled activity is responsible for 
alterations in the physiological processes regulated by c-Abl – proliferation, apoptosis and adherence 
to marrow stroma. 
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Figure 4 – Some of the cellular events triggered by Bcr-Abl kinase activity. Ras activation in 
Bcr–Abl-expressing cells is mediated by Bcr–Abl interaction with the adaptor signalling molecules 
Grb2, Shc, Sos and Dok. The sum of these interactions results in the favouring of Ras in its active 
GTP-bound form. This in turn leads to the activation of Raf-1 serine/threonine kinase activity with 
the subsequent activation of the MEK pathway (resulting in promitotic transcriptional regulation) 
and the PI3K (phosphoinositide 3-kinase) pathway (by phosphorylation of Akt, which leads, via Bad 
phosphorylation and dissociation from Bcl-XL, to an anti-apoptotic signal mediated by Bcl-XL). 
Interestingly, Bcr–Abl-dependent activation of the PI3K pathway has also been shown to be 
mediated by Bcr–Abl interaction with the adaptor molecule Crkl. The guanine-nucleotide-exchange 
factor Vav is known to interact with and act as a phosphorylation substrate of Bcr–Abl. This 
activated Vav subsequently favours the existence of Rac in its active GTP-bound state, leading to its 
effects on cytoskeletal reorganisation. The activation of STAT1 and 5 by phosphorylation has been 
shown in Bcr–Abl-expressing cells, although the mediators of this activation remain unclear. STAT1 
and 5 phosphorylation results in their translocation to the nucleus, where they activate transcription. 
Bcr–Abl inhibits the proteasomal degradation of Fus by a protein kinase C βII (PKCβII) mechanism. 
Fus regulates nucleocytoplasmic export and RNA processing, thereby altering myeloid transcription 
factor (C/EBPα) expression, with subsequent effects on myeloid transcriptional regulation. 
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Figure 5 – The Abl kinase domain in complex with imatinib. Upper panel, overview. The 
activation loop is highlighted in blue. Lower panel, schematic diagram of the interactions between 
imatinib and Bcr-Abl. Nitrogen atoms are coloured blue, oxygen atoms are coloured red, sulphur 
atoms are coloured yellow, protein carbon atoms are coloured brown, imatinib carbon atoms are 
coloured green. Hydrogen-bonds are indicated with dotted lines along with their distances, and 
residues making van der Waals interactions with the inhibitors are circled with dotted lines. 
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Figure 6 – Overview of different mechanisms of resistance that have been observed or 
hypothesized in Ph+ leukemias. Schematic representation of a cell, the oncogenic kinase and the 
downstream signaling pathways. P indicates a phosphorylated protein. The concentration of the 
small molecule inhibitor inside the cell is dependent on its influx and efflux rates. The different sites 
at which resistance can originate are indicated. 
 
 29
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Three-dimensional structure of the Abl kinase domain in complex with dasatinib. 
Left panel, overview. Stick, dasatinib; green, carbon atoms. Blue, NH2-terminal lobe of Abl kinase; 
orange, P-loop; magenta, helix a-C; red, hinge region; pink, COOH-terminal lobe; green, catalytic 
loop; yellow, activation loop. Right panel, cut-away detailed view of dasatinib and nearby residues 
in the ATP-binding site. Green and blue, inhibitor molecules found in the two asymmetric units; 
gray, one protein structure with surface of residues displayed. Dashed lines, hydrogen bonds. 
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AIMS 
 
Imatinib mesylate is a remarkably effective inhibitor of the oncogenic Bcr-Abl tyrosine 
kinase. In some cases, however, the leukemic clone may evolve to evade Bcr-Abl 
inhibition. Point mutations in the Abl KD are frequently observed in patients who 
relapse on imatinib therapy. These mutations disrupt imatinib binding since they affect 
critical residues implicated in direct contact with the inhibitor or prevent Bcr-Abl from 
effectively adopting the specific inactive conformation which imatinib binds. While 
some mutations are associated with a moderate degree of resistance and may therefore 
be overcome by a dose escalation of imatinib, other confer a highly resistant phenotype. 
In such cases, imatinib is no longer effective and alternative treatment strategies, such 
as allogeneic stem cell transplant or a second-generation tyrosine kinase inhibitor, have 
to be considered. In patients with either suboptimal response or evidence of resistance 
to imatinib, the knowledge of the presence, as well as of the type of mutation is 
therefore a useful guide to a rational therapeutic reassessment. During the three year 
research period, studies were conducted in order to  
a) set up and validate a sensitive, high-throughput denaturing-high performance liquid 
chromatography (D-HPLC)-based method for mutation screening of Ph+ patients who 
have a suboptimal response or evidence to resistance to imatinib;  
b) investigate the frequency and the clinical significance of Abl KD mutations in a large 
series of Ph+ patients resistant to imatinib; 
c) assess which pre-existent or emerging Abl KD mutations may be challenging for the 
clinical efficacy of the second-generation tyrosine kinase inhibitor dasatinib in imatinib-
resistant Ph+ patients. 
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PART I: 
SET UP AND VALIDATION OF A NOVEL, SENSITIVE AND HIGH-
THROUGHPUT D-HPLC-BASED ASSAY FOR DETECTION OF ABL 
KD MUTATIONS IN PH+ LEUKEMIA PATIENTS RESISTANT TO 
IMATINIB 
Background 
The encouraging results from trials of imatinib mesylate for the treatment of patients 
with CML have established it as the new standard of care for the disease. Imatinib is a 
potent and selective inhibitor of Bcr-Abl tyrosine kinase, which is known to be 
deregulated in as many as 95% of CML patients, as well as in 20-30% of Ph+ ALL 
patients. Despite high rates of hematologic and cytogenetic responses, primary 
refractoriness and acquired resistance have been observed. Point mutations within the 
KD of the BCR-ABL gene are emerging as the most frequent mechanism for reactivation 
of kinase activity within the leukemic clone.33,41,44-50 A large number of mutations have 
been reported in association with the resistant phenotype, and most of them are well 
characterized in terms of the ability and degree to which they induce resistance.33,44,51 
While some mutations (i.e., Y253F/H, E255K/V, T315I) confer a true resistant 
phenotype and suggest withdrawal of imatinib in favor of alternative therapeutic 
strategies, others (i.e., M244V, F311L, F359V) may be overcome by dose-escalation. 
Thus, in order to optimize therapeutic response, not only the presence of a mutation but 
also the actual amino-acid change should be investigated in patients displaying 
hematologic or cytogenetic resistance to imatinib. A recent study50 has suggested that a) 
in late-CP and AP patients treated with imatinib, mutations can be detected by direct 
sequencing prior to clinical evidence of resistance, thus predicting the subsequent 
course of the disease; and, b) that mutations in the nucleotide-binding loop of the kinase 
region (P-loop) are associated with a particularly poor prognosis. 
For these reasons, routine mutation testing of CML and Ph+ ALL patients who have a 
non-optimal response to imatinib is being introduced in order to assure a more rational 
therapeutic management. Sequencing has been widely used to screen for Abl KD 
mutations in published studies,33,41,44-50 but it is expensive and time-consuming, 
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especially when subcloning of polymerase chain reaction (PCR) products is performed. 
Several alternative methods have been reported, such as allele-specific oligonucleotide 
PCR (ASO-PCR),45 restriction fragment length polymorphisms (RFLP)-based 
assays44,105 and peptide nucleic acid (PNA)-based clamping techniques.106 They are 
more sensitive but seem not to be suitable for large-scale screening of the entire 
spectrum of mutations reported to date. Here we present a novel, rapid and 
straightforward method for monitoring and detection of leukemic cells containing 
imatinib resistance-associated mutations based on PCR amplification and subsequent 
screening of PCR products by denaturing-high performance liquid chromatography (D-
HPLC). 
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Patients and methods 
Patients and samples. The study was retrospectively performed on bone marrow or 
peripheral blood samples obtained from 15 patients with CML and 15 patients with Ph+ 
ALL who had evidence of resistance to imatinib. Resistance was primary (failure to 
achieve a CCgR after 12 months of treatment) in 5 cases and acquired (loss of CCgR, 
loss of HR or progression to AP/BC) in the remaining 25 cases. All patients provided 
informed consent for participation in this study. Mononuclear cells were obtained by 
Ficoll-Hypaque density gradient centrifugation and then stored at –80°C in guanidinium 
thiocyanate until use.  
Positive and negative controls. Cell lines carrying the Y253F, E255K, T315I and 
M351T Abl mutations (kindly provided by Michael Deininger and Brian Druker, 
Oregon Health and Science University, Portland, OR) were used as positive controls. 
G250E- and H396R-mutated amplicons from two patients were subcloned into a 
pCR2.1-TA vector (TOPO TA Cloning Kit; Invitrogen, Carlsbad, CA) and used as 
positive controls, as well. A sample from a CML patient known to be wild-type for Abl 
mutations was used as negative control. 
RNA extraction and reverse transcription (RT)-polymerase chain reaction (PCR). 
Total cellular RNA was extracted from mononuclear cells with the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). RNA was spectrophotometrically quantified by 260 nm 
absorbance and its integrity was assessed by electrophoresis on ethidium bromide-
stained 2% agarose gel. One µg of total cellular RNA was reverse transcribed to cDNA 
in 50 µL final volume using 25 µM of random hexamer primers (Applied Biosystems, 
Foster City, CA) and 200U of M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, 
CA).  
Experimental design of D-HPLC analysis. All samples were analyzed using D-HPLC 
Wave 3500HT DNA Fragment Analysis System (Transgenomic Ltd, Cramlington, UK). 
To increase the sensitivity and specificity of ABL KD amplification we set up a nested-
PCR approach. The first round of amplification was done using 100 ng of cDNA and 
the following primers: either Fwd-BCR-p190 (positioned on exon 1 on BCR mRNA) or 
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Fwd-BCR-p210 (positioned on exons 12/13 on BCR mRNA), and Rev-ABL (positioned 
on exon 10 on ABL mRNA) (Table 1, Figure 1). This procedure ensured that the 
normal, non-rearranged ABL transcript was not analyzed. An initial denaturation step of 
5’ at 95° was followed by amplification for 25 cycles (denaturation: 30” at 95°C; 
annealing: 1’ at 60°C; extension: 2’ 30” at 72°C) and final extension for 7’ at 72°C. 
Reamplification of a 1 µL aliquot was then performed using three internal primer pairs: 
Fwd-ABL-A/Rev-ABL-A, Fwd-ABL-B/Rev-ABL-B and Fwd-ABL-C/Rev-ABL-C 
(Table 1). In this way, the entire ABL KD was divided into three partially overlapping 
fragments of optimal length for D-HPLC analysis, i.e., ABL-A (393 bp, codons 206-
335), ABL-B (482 bp, codons 262-421) and ABL-C (465 bp, codons 371-524)(Figure 
1). For the second rounds of amplification, the following PCR conditions were used: 
initial denaturation step of 5’ at 95°C; amplification for 35 cycles (denaturation: 30’ at 
95°C; annealing: 40” at 60°C; extension: 50” at 72°C); final extension for 7” at 72°C. 
All PCR experiments were performed in 50 µL final volume containing 1.5 U of 
Optimase Polymerase (Transgenomic), 10X reaction buffer (Transgenomic), 200 µM of 
each dNTP (Invitrogen), 1.5 mM MgSO4 (Transgenomic), and 0.5 µM of each primer. 
Specificity and efficiency of the amplification reactions were checked by 
electrophoresis of a 5 µL aliquot on ethidium bromide-stained 2% agarose gel. Using 
Wavemaker software, Version 4.1.40 (Transgenomic), the melting curves were 
calculated to select optimal elution temperatures and gradient conditions to resolve 
heteroduplexes in the three fragments to be screened. Base changes located in various 
positions along a fragment are affected by the melting characteristics of the surrounding 
nucleotides. For example, GC-rich regions of an amplicon lose helicity at higher 
temperatures than AT-rich domains. The melting characteristics of a fragment therefore 
determine the temperature(s) at which the base change will resolve using D-HPLC. 
Wavemaker software identifies melting subdomains with respect to the whole fragment 
sequence and predicts melting temperatures to maximize the resolution of heteroduplex 
and homoduplex peaks within each subdomain – which usually requires an helical 
fraction ranging between 70% and 85%. Principles of D-HPLC-based mutation 
screening are illustrated in Figure 2. Aliquots of 8 µL crude PCR products, preheated 
for 10’ at 96°C and then gradually reannealed for 10’ at room temperature to allow 
heteroduplex formation, were eluted into a DNASep HT column (Transgenomic) at the 
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following temperatures: 61.3°C - 62.4°C - 63.5°C for ABL-A; 60.3°C - 61.1°C - 61.9°C 
for ABL-B; 60.2°C - 60.9°C - 61.2°C for ABL-C. DNA was eluted from the column by 
a linear acetonitrile gradient in 0.1 mM triethylamine acetate buffer (TEAA; 
Transgenomic) at a constant flow rate (1.5 mL/min). Each elution took approximately 3 
minutes. Gradient was formed by mixing buffer A (0.1mM TEAA; Transgenomic) and 
buffer B (0.1mM TEAA, 25% acetonitrile; Transgenomic). Eluted amplicons were 
detected by 260 nm UV absorbance. A wild-type sample was used as a negative control. 
The chromatogram from each tested patient was overlaid with the wild-type profile, and 
samples with extra peak(s) were scored as positive. To ensure that mutations present in 
≥90% of Bcr-Abl-positive cells could not escape D-HPLC detection, for all samples 
studied a mixture of a wild-type negative control and patient PCR products in a 1:1 ratio 
was also run.  
Direct sequencing. Direct sequencing was done in parallel on all the samples using an 
ABI PRISM 3730 (Applied Biosystems). A 20 µL-aliquot of the same PCR product 
analysed by D-HPLC was purified (Qiaquick PCR Purification Kit, Qiagen) and 
sequenced using Big Dye Terminator Cycle Sequencing Kit v1.1 (Applied Biosystems) 
according to manufacturer’s instructions. Removal of unincorporated dideoxy-
nucleotides was done with the Dye-Ex 2.0 Spin Kit (Qiagen). Sequences were 
compared to the wild-type sequence using BLAST [ABL accession number, X16416]. 
Sequence analysis was routinely performed on both strands for each fragment. 
Cloning. In the two cases scored positive by D-HPLC but in whom direct sequencing 
failed to evidence any nucleotide change, the PCR fragment was cloned into a pCR2.1-
TA vector (TOPO TA Cloning Kit; Invitrogen). Twenty independent clones were then 
harvested and sequenced in both directions. 
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Results 
Set up of the D-HPLC assay. The entire KD spans seven exons of the ABL gene (exon 
4 through 10). Therefore, we decided to perform mutation analysis at the RNA level. A 
nested RT-PCR protocol was set up to ensure high sensitivity and to avoid co-
amplification of the normal, non-translocated ABL allele. For the first amplification 
round, two alternative forward primers had to be designed in order to allow 
amplification of both p190- and p210-positive cases. In the second round of PCR, three 
sets of primers were designed so as to amplify three adjacent, partially overlapping 
fragments of optimal length for D-HPLC analysis (393bp, 482 and 465 bp, respectively, 
the recommended length being between 200 and 500 bp; Figure 1). Having established 
the DNA fragment sequences to be studied, we subsequently determined the melting 
temperatures to be used for D-HPLC screening. WAVEmaker software (version 4.1.40; 
Transgenomic) allowed to visualize the position of melting subdomains with respect to 
the whole fragment sequence and to predict melting temperatures to maximize the 
resolution of heteroduplex and homoduplex peaks within each subdomain. Predicted 
temperatures were then assessed for their actual ability to resolve homoduplex and 
heteroduplex peaks by eluting fragments already known to harbour some clinically 
relevant mutations and slight adjustments were made to maximize resolution (Figure 3). 
The elution conditions finally established proved able to allow the detection of all the 
mutations tested. In Figure 4, representative D-HPLC chromatograms are illustrated. 
Wild-type PCR products show a single peak because only homoduplexes are present. 
By comparison, the mutant PCR products show additional peaks, corresponding to 
heteroduplex species, which is more or less resolved depending on the percentage of 
Bcr-Abl-positive cells which harbour the mutation and on the type and position of 
nucleotide substitution within the amplified fragment. 
Sensitivity of the D-HPLC assay. To assess sensitivity, which has been reported to be 
variable in a range of 1-10% depending on the sequence and length of the fragments to 
be analysed,107-109 we prepared limiting dilution experiments by mixing wild type and 
mutant (G250E, Y253F, E255K, T315I, M351T and H396R) plasmids or cell lines at 
the following ratios: 50%:50%; 60%:40%; 70%:30%; 75%:25%; 80%:20%; 83%:17%; 
85%:15%; 88%:12%; 90%:10%; 93%:7%; 95%:5%; 98%:2%; 99%:1%. Representative 
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results for the H396R mutation are shown in Figure 5: the peak corresponding to the 
heteroduplex fraction was still clearly detectable when the mutant represented 10% of 
the total, but a shoulder on the leading edge of the homoduplex peak was still visible 
when the mutant represented 7% and even 5% of the total. For all the mutations tested, 
the lower detection limit of D-HPLC was at least 10%. Sensitivity of direct sequencing 
is shown for comparison in Figure 6. 
Parallel D-HPLC and sequencing analysis of CML and Ph+ ALL patient samples. 
Characteristics of patients and results of D-HPLC and sequence analyses are reported in 
Table 2. In 20 out of 30 (67%) patients, D-HPLC analysis showed an abnormal elution 
profile suggesting the presence of a sequence variation. Sequence analysis confirmed 
the presence of a point mutation in all but two cases (patients no. 27 and 28 in Table 2). 
In order to rule out the possibility that D-HPLC had yielded false positive results, 
cloning was then performed. Sequencing of twenty independent clones for each sample 
revealed that a mutation was actually present at low levels (3/20 and 2/20 clones; Table 
2). Figure 7 shows D-HPLC and direct sequencing outputs for one of these two cases 
(patient no. 28). Conversely, all the samples scored as wild-type by D-HPLC did not 
show evidence of mutations by direct sequencing. In most of the cases, additional 
peak(s) were detected at all three melting temperatures routinely used for D-HPLC 
screening. However, depending on the mutation and on its position within the PCR 
fragment, one of the temperatures was usually most helpful in highlighting additional 
peak(s) clearly resolved from the homoduplex peak, the other two temperatures yielding 
only smaller modifications of the elution profile. In rare cases, the additional peak(s) 
were detected at one temperature only. These findings suggest that, at least in our 
experience, elution at all three temperatures established with the help of WAVEmaker 
software is helpful in order to establish or rule out the presence of a mutation. 
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Discussion 
Since point mutations affecting critical sites within the Abl KD seem to be one of the 
most frequent mechanisms of resistance (with frequencies ranging from 26 to 90% 
depending on the phase of the disease), a mutation screening of patients who have 
suboptimal or no response to imatinib treatment should routinely be performed in order 
to help decision-making on dose-escalation or alternative treatment options. 
So far, sequencing of PCR products (either subcloned or not) has been widely employed 
to search for known and unknown Abl KD variants in CML and Ph+ ALL patients. A 
major limitation of sequencing, however, is the low level of sensitivity. Several authors 
have reported that direct sequencing of ABL PCR products generally reaches a 
sensitivity of 20%.44,48 Subcloning of PCR products followed by sequencing has a 
higher sensitivity, the lower detection limit depending on the number of clones tested. 
By cloning and sequencing of 108 clones per sample (thus reaching a lower detection 
limit <1%) Hofmann et al.52 reported that rare cells bearing the E255K mutation could 
retrospectively be detected prior to imatinib administration in two advanced Ph+ ALL 
patients. The mutation was found in a single clone from each patient. Despite being 
sensitive enough to detect the presence of a point mutation in pre-treatment samples, 
such a method is expensive, cumbersome and time-consuming, and its application for 
screening of large series of patients is unlikely. 
A PCR-SSCP screening method has also been described by the same author.52 The 
method was tested in a cohort of Ph+ ALL patients previously analysed by direct 
sequencing.49 Although PCR-SSCP analysis can generally find conformational changes 
of DNA with a minimum detection level of about 2% to 5%, it proved to be inferior to 
sequencing since there were two imatinib-resistant samples known to have the E255K 
mutation that did not show any shifted band.  
Alternative methods, allowing the detection of specific Abl mutations, have been set up. 
They include PCR-RFLP or modifications,44,105 ASO-PCR45 and PNA-based PCR 
clamping techniques.106 With conventional RFLP,44 a maximum sensitivity of 5% can 
be reached, but the assay is limited to a very small number of Abl mutations (Y253F/H, 
E255K/V, T315I, M351T) for whom the nucleotide change determines the abolishment 
or creation of a restriction site. Recently, an enhanced PCR-RFLP method for T315I 
and Y253F mutations has also been described.105 It relies on the artificial introduction 
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of a TaqI restriction site in the mutant, but not in the wild-type sequences, by using 
mismatched, allele-specific primers. This procedure is meant to rescue only mutation-
containing molecules, thus enhancing the sensitivity of the downstream detection 
methods. This approach proved to be very sensitive, being able to reliably detecting 
artificially-generated mutated amplicons in the presence of 103-fold excess of wild-type 
molecules. Another extremely sensitive technique for detection of specific point 
mutations is ASO-PCR. In a paper by Roche-Lestienne et al,45 ASO-PCR with a 
sensitivity of 1:10000 (10-4) was developed to retrospectively trace the presence of 
F311L, T315I and M351T mutations in 5 mutated patients out of 24 screened at the 
time of resistance by direct sequencing. In all the patients, the mutations turned out to 
be already detectable in the samples collected prior to Imatinib initiation. More recently, 
Kreuzer et al106 developed a PNA-based PCR clamping technique with 1:500 (0.2%) 
sensitivity for Y253H, E255K and T315I mutations. With this method, the E255K 
mutation was again retrospectively detected at diagnosis in a single AP-CML patient 
who never achieved either cytogenetic or hematological remission.  
Despite the fact that the methods cited above proved to be highly sensitive when 
employed for longitudinal screening of resistant patients known to have a specific point 
mutation, some drawbacks exist. ASO-PCR can easily produce false-positive results 
because a single, erroneous primer hybridisation may lead to the generation of artificial 
templates. Moreover, it is not suitable for widespread testing since a panel of more than 
30 specific primers should be employed in order to screen for all the mutations so far 
reported. The latter disadvantage applies also to PNA-based PCR clamping techniques, 
that rely on expensive sets of primers and fluorescent probes for detection of point 
mutations. More importantly, all these techniques can not be used for further 
identification of new point mutations occurring in the KD of Abl protein.  
Here we describe a novel method, which may play an important role as primary 
screening tool. To the best of our knowledge, this is the first application of D-HPLC for 
screening of Abl point mutations in CML or Ph+ ALL patients. D-HPLC is a reverse-
phase ion pair HPLC specifically developed for detection of DNA sequence variations 
such as point mutations, small insertions and deletions.110 Under conditions of partial 
heat denaturation within a linear acetonitrile gradient, heteroduplexes that form in PCR 
samples having internal sequence variations display reduced column retention time with 
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respect to their homoduplex counterparts (Figure 2). The elution profiles for such 
samples are distinct from those having a homozygous sequence, making the 
identification of samples harbouring polymorphisms or mutations a straightforward 
procedure. After D-HPLC analysis, only those samples showing an abnormal elution 
profile are subjected to sequencing in order to determine the precise sequence 
abnormality. Of note, D-HPLC instrument may be coupled to a fragment collector, 
which allows automated fragmentation and purification of the eluted PCR product 
corresponding to the mutated peak, thus increasing the sensitivity of the downstream 
steps required to determine the precise sequence abnormality.109,111 Despite our 
instrument is at present not equipped with a fragment collector, data from the literature 
suggest that, in case of low-level mosaicism, mutations which can not be characterised 
by direct sequencing of unfractionated PCR products are successfully resolved after the 
selective collection of the low-level, mutant heteroduplex peaks. 
Our results in a panel of 30 patients analysed in parallel by D-HPLC and direct 
sequencing showed that D-HPLC is a reliable method for pre-screening of PCR 
products. All the samples showing an abnormal elution profile turned out to have a 
nucleotide change and vice-versa. With respect to sequencing, the method described 
herein is much faster – in contrast with the very cumbersome evaluation of sequence 
data, the evaluation of results by D-HPLC is quite effortless because the investigator 
has to discriminate only between single and multiple peaks in the elution profiles. 
Moreover, PCR-generated products do not need any further manipulation before 
analysis. They are directly loaded onto the D-HPLC column and up to 192 samples can 
be screened in a single run. By using a microtiterplate autosampler, the mutational 
screening can be almost totally automated. Another major advantage is the fact that D-
HPLC analysis is less expensive than sequencing.112 
Our preliminary experiments with serial dilutions of wild-type and mutant ABL PCR 
products at different ratios showed that D-HPLC reaches a lower detection limit 
between 5 and 10% for G250E, E255K, Y253F, T315I, M351T and H396R mutations 
(Figure 4). Such a lower detection limit is in agreement with what has been reported in 
the literature.107-109 Although we have not checked the sensitivity of our method for the 
whole spectrum of mutations reported in the literature, the six mutations tested so far 
are not only the most frequently found in Ph+ patients, but also those which show a 
 41
dramatic increase of IC50 (drug concentration required to inhibit proliferation by 50%) 
to values which can not be reached simply by escalating the dose of imatinib – thus 
indicating the need for an alternative treatment option. The lower detection limit of 
direct sequencing ranges between 20 and 30% (Figure 5). The higher level of sensitivity 
of D-HPLC with respect to sequencing was further testified by two cases of our series. 
In these cases, D-HPLC had clearly shown evidence of a sequence variation, whereas 
subsequent direct sequencing had failed to identify any amino acid substitution. 
However, cloning and sequencing of ten independent clones confirmed that a mutation 
was indeed present at a low level. Sensitivity of D-HPLC is an important advantage 
since a timely detection of mutated clones emerging in resistant patients may allow for a 
more efficient therapeutic intervention. 
In conclusion, the D-HPLC-based method herein described is rapid, sensitive and 
reliable, and may play an important role as a primary screening tool for the detection of 
resistance-associated mutations in CML and Ph+ ALL patients. 
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Tables 
 
 
 
 
 
 
 
 
Primer name 5’ to 3’ sequence Position 
Fwd-BCR p210 GAGCAGCAGAAGAAGTGTTTCAGA BCR, exons 12/13 
Fwd-BCR p190 CAACAGTCCTTCGACAGCAG BCR, exon 1 
Rev-ABL CTTGGAGTGAGGCATCTCAG ABL, exon 10 
Fwd-ABL-A CATCATTCAACGGTGGCCGACGG ABL, exon 4 
Rev-ABL-A GTTGCACTCCCTCAGGTAGTC ABL, exon 6 
Fwd-ABL-B GAAGAAATACAGCCTGACGGTG ABL, exon 4 
Rev-ABL-B CGTCGGACTTGATGGAGAA ABL, exon 7 
Fwd-ABL-C TGGTAGGGGAGAACCACTTG ABL, exon 7 
Rev-ABL-C CCTGCAGCAAGGTACTCACA ABL, exon 10 
 
Table 1 – Sequences of primers used for the amplification of ABL KD. 
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No Disease 
type 
Type of 
resistance 
Months 
on IM 
Bcr-Abl 
type 
D-HPLC 
result 
Sequencing 
result 
Base change Amino acid 
substitution 
1 ALL Acquired 12 p190 MUT MUT ATG>ACG M351T 
2 ALL Acquired 6 p210 MUT MUT CAG>CAT 
GAG>AAG 
GAC>GGC 
Q252H 
E255K         
D276G 
3 ALL Acquired 8 p190 MUT MUT GAG>AAG E255K 
4 ALL Acquired 22 p190 MUT MUT ATG>GTG 
CTG>GTG 
M244V 
L248V 
5 ALL Acquired 9 p190/p210 WT WT - - 
6 ALL Acquired 2 p210 MUT MUT ACT>ATT T315I 
7 ALL Acquired 9 p190 MUT MUT TAC>CAC Y253H 
8 ALL Acquired 7 p210 MUT MUT TTC>GTC F359V 
9 ALL Acquired 5 p190 WT WT - - 
10 ALL Acquired 14 p210 MUT MUT TAC>CAC Y253H 
11 ALL Acquired 9 p210 WT WT - - 
12 ALL Acquired 7 p190 MUT MUT GAG>AAG E255K 
13 ALL Acquired 4 p190 MUT MUT ACT>ATT 
ATG>ACG 
TTG>ATG 
T315I 
M351T 
L387M 
14 ALL Acquired 11 p210 MUT MUT GAG>AAG 
ACT>ATT 
E255K 
T315I 
15 ALL Acquired 3 p190 MUT MUT ACT>ATT T315I 
16 CML Primary 13 p210 WT WT - - 
17 CML Primary 15 p210 WT WT - - 
18 CML Acquired 24 p210 MUT MUT ATG>ACG M351T 
19 CML Acquired 15 p210 WT WT - - 
20 CML Primary 13 p210 WT WT - - 
21 CML Primary 12 p210 WT WT - - 
22 CML Acquired 19 p210 MUT MUT GAG>GGG  E355G 
23 CML Acquired 18 p210 MUT MUT TTC>TTA F317L 
24 CML Acquired 5 p210 WT WT - - 
25 CML Acquired 3 p190 MUT MUT TAC>CAC Y253H 
26 CML Acquired 23 p210 WT WT - - 
27 CML Acquired 13 p210 MUT WT (TAC>CAC) (Y253H, 3/20) 
28 CML Acquired 12 p210 MUT WT (ACT>ATT) (T315I, 2/20) 
29 CML Acquired 33 p210 MUT MUT CAT>CGT 
GAG>AAG 
H396R, 
E459K 
30 CML Primary 13 p210 MUT MUT TTG>ATG G250E 
 
Table 2 – Results of D-HPLC and direct sequencing analyses. In 20 patients, D-HPLC analysis 
showed an abnormal elution profile compatible with the presence of one or more sequence variations 
(MUT). Sequence analysis confirmed the presence of a point mutation in all but two cases. In these 
cases, cloning was performed to increase sensitivity of sequencing. Results of cloning are indicated 
in parentheses, together with the number of positive clones out of the total clones analyzed. 
Conversely, all the samples scored as wild-type (WT) by D-HPLC did not show evidence of 
mutations by direct sequencing. Abbreviations: IM, imatinib. 
 
 44
Figures 
 
 
 
 
 
Figure 1 – KD amplification strategy. Fusion proteins encoded by BCR-ABL vary in size due to 
differences in breakpoint positions and alternative splicing patterns in the BCR gene. In most CML 
and a minority of Ph+ ALL patients, the hybrid transcript displays either a b2a2 or a b3a2 junction, 
resulting from the juxtaposition of BCR exons 13 or 14, respectively, to ABL exon 2. In both cases, 
the protein product is p210BCR-ABL. In the remaining CML and in most Ph+ ALL patients, the fusion 
gene displays the e1a2 junction, i.e. the juxtaposition of BCR exon 1 to ABL exon 2. This transcript 
encodes the p190BCR-ABL protein. In the first amplification round we used a common reverse primer 
located on ABL exon 10 and two alternative forward primers, located either on BCR exon 1 (for 
e1a2-positive patients) or on BCR exons 12/13 (for both b2a2- and b3a2-positive patients). For all 
patients, the second round of amplification was then performed using three primers pairs, in order to 
subdivide the entire ABL KD into three partially overlapping fragments (A, B and C) of optimal 
length for D-HPLC analysis. 
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Figure 2 – Principles of D-HPLC-based mutation screening. Amplified fragments are denatured 
at 96°C for 10 min before they are allowed to reanneal by gradually lowering the temperature. In the 
presence of a mutation, this will generate both homoduplexes (from the reannealing of two wild-type 
or two mutated DNA strands) and heteroduplexes (from the reannealing of a wild-type and a mutant 
DNA strand).On the basis of the GC content of the fragment to be analyzed, column temperature is 
set to maintain partial denaturation. The thermally less stable heteroduplexes denature more 
extensively and consequently, have a shorter column retention time. Depending on several factors, 
including size of fragments, influence of nearest neighbor on the stability of both matched and 
mismatched base pairs and column temperature, the four species can be resolved completely or only 
in part. 
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Figure 3 – Examples of how elution temperature may influence resolution of homoduplex and 
heteroduplex peaks. Upper panel, elution profiles of a BCR-ABL fragment known to be positive for 
the Y253F mutation at 62.8°C (right), 63.1°C (middle), 63.5°C (left). Lower panel, elution profiles 
of a BCR-ABL fragment known to be positive for the G250E mutation at 62.8°C (right), 63.1°C 
(middle), 63.5°C (left). 
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Figure 4 – Examples of D-HPLC outputs for wild-type and mutated samples. In the case of a 
wild-type sample, the elution profile will consist of a single peak because only homoduplexes are 
formed. In the case of a mutated sample, we may observe elution profiles with multiple peaks, or just 
the separation of the homoduplex and heteroduplex species, or even only a small shoulder on the 
leading edge of the homoduplex peak. This is influenced both by the percentage of Bcr-Abl-positive 
cells which harbour the mutation and by the type and position of nucleotide substitution within the 
amplified fragment. 
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Figure 5 – Lower detection limit of D-HPLC analysis. Two plasmids containing a wild-type and a 
H396R-positive amplicon were mixed at different ratios, as indicated. By D-HPLC, with a standard 
UV detector, the additional peak corresponding to the heteroduplex fraction is clearly visible when 
the mutated clone is at a ratio of 7-10%, but a shoulder on the leading edge of the homoduplex peak 
is still evident even at a 5% ratio.  
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Figure 6 – Lower detection limit of direct sequencing. Amplicons from wild-type and Y253F-
positive Ba/F3 cells were mixed at different ratios, as indicated. By direct sequencing, the red peak 
(T; mutated) is still clearly detectable under the green peak (A; wild-type) at a ratio of 30%, less 
clearly detectable at 25% and hardly distinguishable from the background noise at 20%. 
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Figure 7 – Example of sensitive Abl KD mutation detection by D-HPLC. Upper panel, elution 
profiles for fragment B of patient no. 28, overlaid with those of a wild-type control for comparison. 
D-HPLC showed unambiguous evidence of a sequence variation both at the second (61.1°C) and at 
the third elution temperature (61.9°C). Mutation later turned out to be a T315I (ACT>ATT). Lower 
panel, direct sequencing output for the same sample. Only the wild-type peak (“C”; indicated by the 
vertical arrow) could be detected. 
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PART II: 
CONTRIBUTION OF ABL KD MUTATIONS TO IMATINIB 
RESISTANCE IN DIFFERENT SUBSETS OF PH+ LEUKEMIA 
PATIENTS 
Background 
Despite the striking efficacy of imatinib mesylate for the treatment of Ph+ leukemias, 
resistance is observed in a proportion of patients, especially those with Ph+ ALL or 
advanced stage CML. Through the contribution of several research groups, the past four 
years have brought us considerable knowledge on the molecular mechanisms 
underlying resistance to imatinib (reviewed in 32). Reactivation of Bcr-Abl tyrosine 
kinase activity within the leukemic clone is known to be most commonly associated 
with the emergence of point mutations in the Abl KD that impair imatinib binding 
without affecting ATP binding or kinase activity.113,114 To date, more than forty 
different amino acid substitutions have been reported,33,41,44-50,115,116 and most of them 
have already been characterized in terms of the extent to which they abrogate sensitivity 
to imatinib.33,44,46,51 However, very few studies have been published on large and 
homogeneous series of resistant patients, and this has made it difficult to establish to 
what extent mutations do account for or at least contribute to resistance in its different 
clinical manifestations or in distinct disease categories. 
To shed further light on this issue, we have collected and analyzed for the presence of 
Abl KD mutations samples from 370 CML or Ph+ ALL patients treated with imatinib at 
multiple centers of the GIMEMA Working Party on CML, who had clinical evidence of 
hematologic or cytogenetic resistance.  
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Patients and Methods 
Patients and definitions. Between January 2004 and November 2005, bone marrow 
and/or peripheral blood samples from 370 CML or Ph+ ALL patients at the time of first 
evidence of resistance to imatinib (according to the definitions given below) were 
collected from multiple centers of the GIMEMA Working Party on CML and analyzed 
at our Institution for the presence of Abl KD mutations. All the patients were receiving 
imatinib at the standard doses of 400-600 mg/d. Informed consent for participation to 
this study was provided according to the Declaration of Helsinki. CP, AP and BC were 
defined as in recent studies.101,102,117,118 Clinical features of lymphoid BC resembled Ph+ 
ALL and therefore these diseases were analyzed together. Primary hematologic 
resistance was defined as failure to achieve and sustain any HR for at least four weeks 
during the first three months of imatinib therapy. Primary cytogenetic resistance was 
defined as failure to achieve and sustain a CCgR (100% Ph-negative metaphases, based 
on the evaluation of a minimum of 20 marrow cells) for at least four weeks during the 
first 12 months of imatinib therapy. Acquired resistance was defined either as loss of 
CCgR, or loss of HR, or progression to AP or BC. Sensitivity and reliability of mutation 
detection is very dependent on the quality and integrity of RNA.50 Given that no bedside 
RNA stabilization was done before shipment of blood or bone marrow to our 
Institution, samples were first of all assessed for the level of BCR-ABL and ABL 
transcripts 119,120 and were subjected to mutation screening only if the RNA obtained 
from the sample contained a measurable level of BCR-ABL transcript and the ABL 
control gene level indicated a nondegraded RNA. Samples from 73 (20%) patients were 
therefore discarded because of inadequate RNA quality, which was influenced neither 
by patient clinical features nor by type of resistance, but depended only on shipment 
conditions and time to delivery. Two hundred and ninety-seven patients were therefore 
evaluable for the aims of this study. Median age at imatinib start was 49 years (range, 
17-70). Median time between diagnosis and imatinib start was 32 months (range, 0-
160). Median duration of imatinib was 25 months (range, 4-42). Classification of 
patients in terms of disease phase and type of resistance is shown in Table 1. 
RNA extraction and RT-PCR. Total cellular RNA was extracted from leukocytes and 
reverse transcribed as previously described.  
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D-HPLC analysis. Scanning of the Abl KD for the presence of mutations was 
performed as previously described. Briefly, after a first amplification of a fragment 
spanning both the BCR-ABL breakpoint and the ABL KD, three overlapping amplicons 
covering the KD (amino acids 206-335, 262-421 and 371-524) were generated by 
nested polymerase chain reaction and screened for the presence of sequence variations 
by D-HPLC (WAVE 3500-HT; Transgenomic, Cramlington, UK). Sensitivity of the 
assay ranged between 5 and 10% (data not shown). To ensure that mutations present in 
≥90% of Bcr-Abl-positive cells could not escape D-HPLC detection, for all samples 
studied a mixture of wild-type and patient PCR products in a 1:1 ratio was also run.  
Direct sequencing. Direct sequencing of D-HPLC-positive cases was done on an ABI 
PRISM 3730 (Applied Biosystems, Foster City, CA), as previously described. 
Sensitivity of the method was 20-25% (data not shown).  
Statistical analysis. Fisher’s exact test was used to test for differences in mutation 
frequency among categories of patients. Analyses were performed using the SPSS 
software (SPSS Inc., Chicago, IL). 
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Results 
D-HPLC and sequence analyses for Abl KD mutations. D-HPLC analysis showed 
evidence of one or more sequence variations in 127/297 (43%) patients. Subsequent 
direct sequencing failed to detect any nucleotide substitution in 18 patients (4 CP 
patients treated with imatinib frontline, 12 CP patients post-IFN failure, 1 AP patient 
and 1 Ph+ ALL), but in all cases presence of a mutation became evident when sequence 
analysis was repeated on a second sample taken after one to two months from D-HPLC 
analysis. In 8 patients (2 Ph+ ALL, 2myBC, 2 lyBC, 1 AP and 1 CP post-IFN-α failure) 
multiple mutations simultaneously occurred so that, overall, 135 mutations were 
detected. Mutations mapped to 17 codons, the most frequent ones being E255K/V (21 
patients, 17%), Y253F/H (17 patients, 13%), T315I (15 patients, 12%), M351T (14 
patients, 11%), F359V/I (14 patients, 11%), M244V (13 patients, 10%), G250E (13 
patients, 10%). Distribution and relative frequency of KD mutations found in our study 
are shown in Figure 1. Mutations falling within the ‘P-loop’ region (codons 248 through 
255) were found in 58 patients (46% of all mutated patients). 
Frequency and distribution of mutations according to disease phase at the time of 
analysis. Mutations were found in 54/198 (27%) patients in first CP (6/44 (14%) treated 
with imatinib frontline, 48/154 (31%) treated with imatinib after IFN-α failure), 11/21 
(52%) AP patients, 24/32 (75%) myBC patients and 38/46 (83%) lyBC/Ph+ ALL 
patients (CP vs. AP, P=.02; AP vs. BC, P=.02; CP vs. BC, P<.0001) (Table 2). When 
we examined position and relative frequency of mutations by disease phase, we noticed 
a trend towards the preferential association of P-loop and T315I mutations and 
advanced stages of disease (Figure 2).  
Frequency and distribution of mutations according to type of resistance. Mutations 
were associated in 45/152 (30%) patients with primary resistance (8/18 hematologic and 
37/134 cytogenetic) and in 82/145 (57%) patients with acquired resistance (12/52 
patients who lost CCgR, 18/33 patients who lost HR, 52/60 patients who progressed to 
AP/BC) (primary vs. acquired, P<.0001) (Table 3). Primary or acquired resistance did 
not seem to significantly differ in terms of type or relative frequency of mutations 
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responsible for (Figure 3), but 40 out of 52 mutated patients who had progressed to 
AP/BC harboured P-loop or T315I mutations (data not shown). 
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Discussion 
Aim of the present study was to investigate the presence of Abl KD mutations in a large 
series of Ph+, imatinib-resistant cases, in order to assess to what extent mutations do 
account for or at least contribute to resistance in its different clinical manifestations or 
in distinct disease categories. Of 297 CML and Ph+ ALL patients with adequate RNA 
quality for BCR-ABL PCR amplification and D-HPLC/sequencing analyses, 127 (43%) 
showed evidence of one or more KD mutations. Such an incidence is somewhat lower 
than expected, but this is mainly due to the high degree of variability in mutation 
frequencies we observed among different subsets of patients. Indeed, when we 
separately considered the mutation frequencies by disease phase (Table 2) we could 
observe that in CP patients the contribution of KD mutations to the resistant phenotype 
was much lower than in AP and BC patients, with lymphoid BC and Ph+ ALL patients 
being the ones with the greatest likelihood of harbouring one or even multiple 
mutations. Similarly, mutation incidence in patients with primary resistance was much 
lower than in patients with acquired resistance (Table 3). The relatively low overall 
frequency of mutation in our series with respect to other published studies may 
therefore be explained by the predominance of CP patients (67%) as well as by the 
relatively high number of patients with primary resistance (51%).  
The difference in mutation incidence between disease phases leads to several 
considerations. On one hand, it points towards advanced phase CML and Ph+ ALL 
cases as patients at high-risk for the emergence of resistance-associated mutant clones. 
There are currently no published data supporting the evidence that a systematic 
screening allowing for an early detection of emergent KD mutations is more beneficial 
than examining ABL sequences only in case overt resistance to imatinib is observed. 
However, our data suggest that at least in the setting of advanced phase CML or Ph+ 
ALL patients it might be worth assessing – ideally in the context of a prospective study 
– whether a regular mutation monitoring may assist clinicians in treatment optimization. 
 On the other hand, the evidence that in CP patients mutations account for 
approximately a quarter of resistant cases only highlights the need to find out which 
is/are the actual predominant mechanism(s) of resistance acting in this setting which 
now gathers the overwhelming majority of CML patients on imatinib therapy. BCR-
ABL gene amplification and additional chromosomal aberrations are also known to be 
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associated with imatinib resistance,41,44 but they seem to play a role mainly in advanced 
CML phases. Point mutations in Bcr or Abl regions other than the KD have been 
hypothesized based on results of an in vitro saturation mutagenesis screening for 
mutations conferring resistance to imatinib121 and on the assumption that any amino 
acid substitution favoring the active conformation of Bcr-Abl (to whom imatinib is 
unable to bind) may confer resistance, but have never been described in patients as yet. 
Significantly lower expression of the drug transporter hOCT1, involved in imatinib 
influx, has recently been reported in some CP patients with primary cytogenetic 
resistance62 and is an issue which deserves further elucidation. Among CP patients, 
however, mutation incidence in those who had received imatinib after IFN-α failure was 
approximately  twice as high as in those who had received imatinib as first-line therapy 
(31% as against 14%). Such an intriguing difference between early- and late-CP 
supports the hypothesis that mutations tend to accumulate during the natural course of 
the disease as a result of a progressively increasing genetic instability and are therefore 
a feature of CML clinical deterioration and not necessarily a phenomenon observed only 
against a background of imatinib exposure. This would fit with the recent observation 
that KD mutations may be detected in a substantial fraction of imatinib-naïve patients 
with advanced phase CML.53 
Even though the codons affected by mutations were seventeen and the relative 
frequencies of each single amino acid substitution were consequently low, we could 
observe that P-loop and T315I mutations were more recurrently found in advanced stage 
CML and Ph+ ALL patients (Figure 2). Even more importantly, in most cases there 
seemed to be a close association between the emergence of these mutant clones and 
progression of patients from CP to AP or BC. The P-loop (amino acids 248 through 
256) is a highly conserved region responsible for ATP phosphate binding.31,122 Amino 
acid 315 is the so-called ‘gatekeeper’ residue – the hydroxyl group of threonine 315 
forms a hydrogen bond with imatinib, and the side chain also sterically controls the 
binding of the inhibitor to the ATP-binding site. Substitution of threonine with a bulkier 
and more hydrophobic isoleucine abolishes the hydrogen bond and determines a steric 
clash that renders the active site inaccessible not only to imatinib but also to most 
second-generation inhibitors.123 Among several mutants, the G250E, Q252H, Y253F/H, 
E255K/V, and T315I are the ones which displayed the highest IC50 values in 
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biochemical and cellular assays.51 But the virtually complete insensitivity to imatinib 
conferred by such mutations is likely not to be the only explanation for such a 
particularly aggressive leukemic phenotype. It has actually been hypothesized that the 
ones above may be gain-of-function mutants, characterized by a greater transforming 
potency with respect to other mutant forms or to wild-type Bcr-Abl, at least under the 
selective pressure of imatinib.47,124  
While it is rather well established that mutations are the main cause of resistance in 
relapsing patients, few and contrasting data are currently available about the incidence 
of mutations in patients with primary resistance to imatinib.44,49,125 Some authors even 
hypothesized that resistance mechanisms other than Abl KD mutations may underlie 
lack of response to imatinib. To the best of our knowledge, our is the first study 
investigating the contribution of Abl KD mutations to primary resistance in a large 
series of patients. We show here that mutations can be found also in patients with 
primary resistance, even though at a much lower frequency, and that there is no 
difference between primary and acquired resistance in terms of the identity of amino 
acid substitutions responsible for. But some 70% of patients with primary resistance do 
not have evidence of KD mutations. Again, since the contribution of KD mutations to 
resistance in this setting of patients is modest, additional work is needed to find out 
whether one or more yet unidentified mechanism(s) exist. 
According to recently published guidelines on CML management,118 mutation analysis 
of patients treated with imatinib is suggested in case there is evidence of inadequate 
response or any sign of loss of response. The knowledge of whether a KD mutation is 
present, as well as of the type of mutation, may contribute to a timely and rational 
therapeutic management, especially now that the armamentarium against CML and Ph+ 
ALL is about to include second-generation inhibitors like dasatinib (BMS-354825)72 
and nilotinib (AMN-107).73 For those patients harbouring mutations which are known 
to confer only moderate resistance to imatinib, dose-escalation may be beneficial. For 
those who have evidence of mutations conferring total insensitivity to imatinib, 
allogeneic transplant if feasible or alternative inhibitors have to be considered. Our data 
support the notions that a) mutation analysis should be performed both in case of 
imatinib failure and in case of loss of hematologic or cytogenetic response; b) the 
subsets of advanced phase CML and Ph+ ALL patients are to be considered a high-risk 
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group; c) the occurrence of P-loop, or T315I mutations in patients treated with imatinib 
should trigger a rational reconsideration of the therapeutic strategy. 
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Tables 
 
 
 
 
 
 
 
 
 All Primary resistance (%) 
Acquired resistance 
(%) 
Total no. 297 152 (51) 145 (49) 
CP 198 116 (59) 82 (41) 
   -  IM frontline 44 28 (64) 16 (36) 
   -  IM after IFN-α failure 154 107 (69) 47 (31) 
AP 21 5 (24) 16 (76) 
myBC 32 5 (16) 27 (84) 
lyBC/Ph+ ALL 46 7 (15) 39 (85) 
 
Table 1 – Classification of the patient population under study. 
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 All Mutated (%) 
Total no. 297 127 (43) 
CP 198 54 (27) 
     - IM frontline 44 6 (14) 
     - IM after IFN-α failure 154 48 (31) 
AP 21 11 (52) 
myBC 32 24 (75) 
lyBC/Ph+ ALL 46 38 (83) 
 
Table 2 – Frequency of mutations according to disease phase. 
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 All Mutated (%) 
Total no. 297 127 (43) 
Primary resistance 152 45 (30) 
             - hematologic 18 8 (44) 
             - cytogenetic 134 37 (28) 
Acquired resistance 145 82 (57) 
             - loss of CCgR 52 12 (23) 
             - loss of HR 33 18 (55) 
             - progression to AP/BC 60 52 (87) 
 
Table 3 – Frequency of mutations according to type of resistance. 
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Figures 
 
 
 
 
 
 
 
Figure 1 – Distribution and relative frequency of Abl KD mutations found in our study. 
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Figure 2 – Position and relative frequency of mutations according to disease phase. 
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Figure 3 – Position and relative frequency of mutations according to type of resistance. 
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PART III: 
ABL KD MUTATIONS ASSOCIATED WITH RESISTANCE TO 
DASATINIB IN PH+ LEUKEMIA PATIENTS 
Background 
The problem of resistance to imatinib in Ph+ leukemia patients has prompted the design 
of several second-generation Bcr-Abl inhibitors. One of these, dasatinib (BMS-354825), 
is now in clinical development.72 In vitro assays69,70 and crystallographic studies71 have 
suggested that the less stringent conformational requirements for Bcr-Abl binding are 
likely to render dasatinib active against many of the KD mutants responsible for 
imatinib resistance. One remarkable exception appears to be the T315I, which has been 
shown to disrupt a hydrogen bond critical for dasatinib binding and to create a steric 
hindrance which interferes with the entrance of the inhibitor into the ATP-binding site.  
In order to assess which pre-existent or emerging mutations are challenging for 
dasatinib clinical efficacy, we analyzed BCR-ABL KD sequences before and during 
treatment in Ph+ leukemia patients who failed to respond to or relapsed on dasatinib 
therapy. 
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Patients and methods 
Patients and definitions. We have treated in the phase II program with dasatinib 70 mg 
twice daily  a total of forty-five patients with CML (n=35) or Ph+ ALL (n=10) who 
were resistant to or intolerant of imatinib. Median age was 50 years (range, 18-74); 
median duration of CML was 32 months (range, 4-158); median duration of imatinib 
was 17 months (2-57). At the time of writing, with a median follow-up of 12 months 
(range, 1-19), twenty-one patients have had evidence either of primary or of acquired 
resistance, defined as failure to achieve any HR or loss of HR during treatment, 
respectively. All the patients provided written informed consent for participation in this 
study. Assessment of HR was done according to the criteria already described for the 
phase I study.72 Assessment of cytogenetic response (CgR) was performed on 30 
marrow metaphases with standard banding techniques.126  
RNA extraction and RT-PCR. Total cellular RNA was extracted from leukocytes and 
reverse transcribed as previously described.  
D-HPLC analysis. Mutation analysis of the BCR-ABL KD was performed as previously 
described. Briefly, after a first amplification of a fragment spanning both the BCR-ABL 
breakpoint and the ABL KD, three overlapping fragments covering the entire KD 
(amino acids 206 through 524) were generated by nested polymerase chain reaction and 
screened for the presence of sequence variations by D-HPLC (WAVE 3500-HT; 
Transgenomic, Cramlington, UK). Sensitivity of the assay ranged between 5 and 10% 
(data not shown). To ensure that mutations present in ≥90% of Bcr-Abl-positive cells 
could not escape D-HPLC detection, for all samples studied a mixture of wild-type and 
patient PCR products in a 1:1 ratio was also run. 
Direct sequencing. In D-HPLC-positive cases, subsequent sequencing was performed 
on an ABI PRISM 3730 (Applied Biosystems, Foster City, CA) to characterize the 
precise nucleotide substitution(s). Sensitivity of the method was 20-25% (data not 
shown). 
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Results 
Abl KD mutations associated with primary resistance to dasatinib. Eight patients had 
primary resistance to dasatinib (patients no. 1-8 in Table 1 and Figure 1). In all these 
patients, a T315I or a F317L mutation was already detectable before the onset of 
treatment or became detectable after one month. The mutations persisted up to the time 
of disease progression (Figure 1), which occurred at a median of 1.5 months (range, 1-
4) from dasatinib start despite the fact that in 5/8 cases (patients no. 1, 3, 4, 6 and 8; 
Figure 1) a dose increase to 90 or 100 mg twice a day was attempted. 
ABL KD mutations associated with acquired resistance to dasatinib. Thirteen patients 
had acquired resistance to dasatinib (patients no. 9-21 in Table 2 and Figure 1). Relapse 
occurred after a median of 7 months (range, 3-15) from dasatinib start. Mutation 
analysis performed before the onset of treatment showed that five of these patients had a 
wild-type BCR-ABL sequence, while the remaining eight patients had evidence of 
various imatinib-resistant KD mutations (G250E, Y253H, E255K, D276G, M351T, 
L387M; Table 2 and Figure 1). At the time of relapse, however, most of the original 
mutant clones had disappeared whereas mutations either at codon 315 or at codon 317 
had invariably emerged in 20/21 patients (Table 2 and Figure 1). Interestingly, in two of 
these cases relapse was associated with the selection of novel amino acid substitutions – 
a threonine to alanine change at codon 315 (T315A) and a phenylalanine to isoleucine 
change at codon 317 (F317I). In the remaining patient (no. 20 in Table 2 and Figure 1) a 
previously unreported K356R mutation was detected. 
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Discussion 
These data complement in vitro observations69,70 as well as structural studies,71 
confirming that the T315I mutation is highly resistant to dasatinib. In imatinib-
resistant/intolerant CML or Ph+ ALL patients, the T315I accounted for dasatinib 
treatment failure in 13 of 21 cases. All the five patients (no. 2, 3, 5, 6 and 7 in Table 1 
and Figure 1) who had already evidence of a T315I before the onset of dasatinib – at 
least by direct sequencing – failed to achieve any response. In the remaining eight 
patients, the T315I outgrew during treatment. In patients no. 1 and 8 it became 
detectable after only one month of therapy and no HR could be observed. In patients no. 
9, 11, 12, 13, 14 and 16, the T315I emerged after the patient had achieved a HR and in 
most cases even a CgR, and invariably preceded or accompanied relapse. Interestingly, 
an additional patient (no. 17) was found to harbour a variant amino acid substitution at 
codon 315 (T315A) at the time of relapse. The T315A has never been reported in 
patients, but has recently been identified in an in vitro saturation mutagenesis screening 
for Bcr-Abl mutants conferring resistance to dasatinib.127 Ba/F3 cells expressing the 
T315A-Bcr-Abl were shown to have a 90-fold higher IC50 with respect to those 
expressing wild-type Bcr-Abl when incubated with dasatinib.127 Of note, the increase in 
imatinib IC50 for this mutant was only 2.4-fold, suggesting that in such a case resuming 
imatinib alone or in combination might prove effective. In our patient, rechallenging 
with imatinib at the dose of 800 mg/d was actually attempted after dasatinib 
discontinuation and resulted in a reduction of leukocytosis and a decrease of the 
proportion of T315A- and F317L-positive cells, but at the same time promoted the rapid 
selection of an additional G250E mutation. For this reason, and because of disease 
persistence, imatinib was withdrawn after seven weeks. The patient is now being treated 
with nilotinib with normalization of blood cell count, but the T315A and the G250E 
were still detectable after two months of treatment. 
In six of 21 patients, lack of response or relapse were strikingly associated with the 
presence or the selection of a mutation at codon 317 (F317L in five cases, F317I in one 
case). Co-crystal studies have demonstrated that the aromatic ring in the side chain of 
phenylalanine 317 directly interacts with the pyrimidine and thiazole rings of 
dasatinib.71 Accordingly, several amino acid substitutions affecting residue 317 were 
observed in the in vitro saturation mutagenesis screening for dasatinib-resistant mutants, 
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including both the imatinib-resistant F317L and presently unreported variants like 
F317V, and F317S, and the F317I found in our patient.127 The F317L has been shown to 
induce a 9 to 13.5-fold increase of dasatinib IC50 in cellular assays.69,127,128 In two 
patients, a dose increase from 70 to 90 or 100 mg twice daily was attempted but this did 
not succeed in eliminating the F317L/I-positive mutant clone.  
Finally, in one patient of our series (no. 20) a K356R mutation became detectable by 
direct sequencing at the time of relapse. This mutation has never been reported, either in 
vitro or in vivo, in association with imatinib or dasatinib resistance. It is unclear whether 
in this patient the emergence of the K356R was the actual determinant of resistance, or 
some other mechanism might rather have intervened and ultimately determined the 
expansion of the Bcr-Abl-positive cells harbouring the mutation. 
In some cases (patients no. 10, 11, 14, 16 and 17), pre-existing dasatinib-sensitive 
mutant clones (i.e., E255K, Y253H, D276G) were selectively eliminated, but soon 
replaced by a newly-emerged dasatinib-resistant T315I- or F317L-positive clone. In 
other cases (patients no. 8, 13, 18 and 21), the T315I- or F317L-positive cells were 
selected by dasatinib treatment as a subclone of the original, imatinib-resistant mutated 
clone, since both the original and the newly outgrown mutations were detected on the 
same allele (data not shown). Given that this was invariably observed in advanced-CML 
and Ph+ ALL cases, it can be hypothesized that in this clinical setting the high rate of 
genomic instability may foster the development over time of multiple mutations within 
the same or in different Bcr-Abl-positive sub-clones, which will then be selected or de-
selected depending on the spectrum of sensitivity and resistance to the inhibitor 
employed. 
At the time of relapse, resistance-associated mutations were clearly detected by direct 
sequencing since they always accounted for at least 50% of the Bcr-Abl-positive cells 
(Figure 1). However, the more sensitive D-HPLC analysis116,129 could in some cases 
(patients 9, 11, 19, 20 and 21) detect the emergence of the mutations one to three 
months earlier than sequencing, thus proving a particularly valuable tool for monitoring 
imatinib-resistant patients treated with second-generation inhibitors. 
The T315I is usually observed in approximately 15% of Ph+ leukemia patients who are 
resistant to imatinib,130-132 but is likely to become the prevalent mutation in those who 
fail second-line treatment with dasatinib or other novel inhibitors for whom threonine 
 71
315 is a critical binding residue.87 At present, there is only one compound (MK-0457, 
also known as VX-680) in clinical development in the field of leukemias that has been 
documented to be effective in CML and Ph+ ALL patients harbouring the T315I 
mutation,96,97 since it has been shown not to require interaction with threonine 315 for 
efficient binding and inhibition in recent co-crystal studies.95 Observation of a larger 
series of patients is required to assess whether the F317L will turn out to be another 
problematic mutant in dasatinib-treated patients. 
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Tables 
 
 
 
 
Pt 
no. Sex Age
Disease phase  
or type 
Reason for 
imatinib 
discontinuation
Mutation status 
before dasatinib start
Best      
HR on 
dasatinib
Best      
CgR on 
dasatinib
Months on 
dasatinib 
Mutation status        
at progression 
Primary resistance 
1 M 48 CML/AP resistance WT NR NR 4 T315I 
2 F 61 CML/AP resistance T315I NR N.E. 1 T315I 
3 F 33 CML/myBC resistance T315I NR N.E. 1 T315I 
4 M 62 CML/myBC resistance F317L NR NR 3 F317L 
5 F 38 CML/lyBC resistance T315I NR N.E. 1 T315I 
6 F 21 Ph+ ALL resistance T315I, M351T, L387M NR N.E. 2 T315I, M351T, L387M 
7 M 40 Ph+ ALL resistance T315I NR N.E. 1 T315I 
8 M 37 Ph+ ALL resistance F359V NR N.E. 2 F359V, T315I 
 
Table 1 – Patients with primary resistance to dasatinib: characteristics and response to dasatinib according to mutational status. Definitions of 
hematologic and cytogenetic response as reported in 72. Abbreviations: Pt, patient; M, male; F, female; AP, accelerated phase; myBC, myeloid blast crisis; 
lyBC, lymphoid blast crisis; WT, wild-type; NR, no response; N.E., not evaluated. 
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Pt 
no. Sex Age
Disease phase  
or type 
Reason for 
imatinib 
discontinuation 
Mutation status 
before dasatinib 
start 
Best       
HR on 
dasatinib 
Best       
CgR on 
dasatinib 
Months 
on 
dasatinib 
Mutation status       
at progression 
Acquired resistance 
9 M 35 CP intolerance WT CHR mCgR 15 T315I 
10 F 60 CML/myBC intolerance G250E NEL NR 8 F317L 
11 M 25 CML/lyBC resistance Y253H CHR CCgR 9 T315I 
12 M 27 CML/lyBC resistance WT CHR CCgR 4 T315I 
13 F 26 CML/lyBC resistance E255K CHR NR 3 E255K, T315I 
14 F 60 CML/lyBC intolerance D276G CHR CCgR 7 T315I 
15 M 37 CML/lyBC resistance WT CHR PCgR 9 F317L 
16 M 41 Ph+ ALL resistance E255K CHR N.E. 4 T315I 
17 M 18 Ph+ ALL resistance Y253H CHR CCgR 13 T315A, F317L 
18 M 64 Ph+ ALL resistance M351T CHR CCgR 13 M351T, F317L 
19 M 73 Ph+ ALL intolerance WT CHR CCgR 6 F317I 
20 F 55 Ph+ ALL intolerance WT CHR CCgR 4 K356R 
21 F 63 Ph+ ALL resistance L387M CHR CCgR 5 F317L, L387M 
 
Table 2 – Patients with acquired resistance to dasatinib: characteristics and response to dasatinib according to mutational status. Definitions of 
hematologic and cytogenetic response as reported in 72. Abbreviations: Pt, patient; M, male; F, female; CP, chronic phase; myBC, myeloid blast crisis; lyBC, 
lymphoid blast crisis; WT, wild-type; CHR, complete hematologic response; NEL, no evidence of leukemia; mCgR, minor cytogenetic response; NR, no 
response; CCgR, complete cytogenetic response; PCgR, partial cytogenetic response; N.E., not evaluated. 
 
 74
Figures 
 
 
 
 
Figure 1 – Mutation monitoring and follow-up of patients. Open squares represent wild-type 
ABL; full squares represent mutated ABL as detected by direct sequencing. Mutations at codons 315 
and 317 are highlighted in red. The degree of shading indicates the relative proportion of mutant 
with respect to wild-type, as estimated by relative peak heights in sequence chromatograms. 
Dasatinib dose increase to 90 or 100 mg twice daily was attempted in nine cases, as indicated. The 
time the best hematologic and cytogenetic responses were achieved is indicated by an arrow. 
Abbreviations as in Tables 1 and 2. 
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